18167020 true 18010625 us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent 0001039065--06-30 2020 Q3 false 0 0 0 0 0001039065 srt:MaximumMember us-gaap:CommonStockMember 2020-04-30 0001039065 srt:MaximumMember us-gaap:CommonStockMember 2018-03-31 0001039065 us-gaap:CommonStockMember 2019-07-01 2020-03-31 0001039065 us-gaap:RetainedEarningsMember 2020-03-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001039065 us-gaap:RetainedEarningsMember 2019-12-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001039065 us-gaap:RetainedEarningsMember 2019-06-30 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001039065 us-gaap:RetainedEarningsMember 2019-03-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001039065 us-gaap:RetainedEarningsMember 2018-12-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001039065 2018-12-31 0001039065 us-gaap:RetainedEarningsMember 2018-06-30 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001039065 us-gaap:EmployeeStockOptionMember 2019-06-30 0001039065 osis:AmendedAndRestatedEquityParticipationPlan2006Member 2019-07-01 2020-03-31 0001039065 osis:IncentiveAwardPlan2012Member 2020-03-31 0001039065 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0001039065 osis:PerformanceBasedRestrictedStockUnitsMember 2019-07-01 2020-03-31 0001039065 osis:PerformanceBasedRestrictedStockUnitsMember 2018-07-01 2019-03-31 0001039065 us-gaap:EmployeeSeveranceMember 2020-03-31 0001039065 osis:ChargesRelatedToLitigationMember 2020-03-31 0001039065 us-gaap:EmployeeSeveranceMember 2019-06-30 0001039065 osis:ChargesRelatedToLitigationMember 2019-06-30 0001039065 us-gaap:CorporateMember 2019-01-01 2019-03-31 0001039065 us-gaap:LeaseholdImprovementsMember 2020-03-31 0001039065 us-gaap:LandMember 2020-03-31 0001039065 us-gaap:FurnitureAndFixturesMember 2020-03-31 0001039065 us-gaap:EquipmentMember 2020-03-31 0001039065 us-gaap:ConstructionInProgressMember 2020-03-31 0001039065 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-03-31 0001039065 us-gaap:ComputerEquipmentMember 2020-03-31 0001039065 us-gaap:BuildingAndBuildingImprovementsMember 2020-03-31 0001039065 osis:ComputerSoftwareImplementationInProcessMember 2020-03-31 0001039065 us-gaap:LeaseholdImprovementsMember 2019-06-30 0001039065 us-gaap:LandMember 2019-06-30 0001039065 us-gaap:FurnitureAndFixturesMember 2019-06-30 0001039065 us-gaap:EquipmentMember 2019-06-30 0001039065 us-gaap:ConstructionInProgressMember 2019-06-30 0001039065 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-06-30 0001039065 us-gaap:ComputerEquipmentMember 2019-06-30 0001039065 us-gaap:BuildingAndBuildingImprovementsMember 2019-06-30 0001039065 osis:ComputerSoftwareImplementationInProcessMember 2019-06-30 0001039065 osis:CxrLimitedMember 2020-01-01 2020-03-31 0001039065 osis:CxrLimitedMember 2019-07-01 2020-03-31 0001039065 osis:CxrLimitedMember 2019-01-01 2019-03-31 0001039065 osis:CxrLimitedMember 2018-07-01 2019-03-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001039065 2019-07-01 0001039065 osis:DifferenceBetweenLeasesGuidanceInEffectBeforeAndAfterTopic842Member 2019-06-30 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2020-01-01 2020-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2020-01-01 2020-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2020-01-01 2020-03-31 0001039065 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-03-31 0001039065 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2019-07-01 2020-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2019-07-01 2020-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2019-07-01 2020-03-31 0001039065 us-gaap:IntersegmentEliminationMember 2019-07-01 2020-03-31 0001039065 us-gaap:CorporateNonSegmentMember 2019-07-01 2020-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2019-01-01 2019-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2019-01-01 2019-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2019-01-01 2019-03-31 0001039065 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-03-31 0001039065 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2018-07-01 2019-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2018-07-01 2019-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2018-07-01 2019-03-31 0001039065 us-gaap:IntersegmentEliminationMember 2018-07-01 2019-03-31 0001039065 us-gaap:CorporateNonSegmentMember 2018-07-01 2019-03-31 0001039065 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001039065 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001039065 us-gaap:CorporateMember 2018-07-01 2019-03-31 0001039065 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2019-07-01 2020-03-31 0001039065 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2019-07-01 2020-03-31 0001039065 us-gaap:RevolvingCreditFacilityMember 2019-07-01 2020-03-31 0001039065 us-gaap:LineOfCreditMember 2020-03-31 0001039065 2019-12-31 0001039065 us-gaap:TrademarksMember 2020-03-31 0001039065 us-gaap:InProcessResearchAndDevelopmentMember 2020-03-31 0001039065 us-gaap:TrademarksMember 2019-06-30 0001039065 us-gaap:InProcessResearchAndDevelopmentMember 2019-06-30 0001039065 us-gaap:AccountingStandardsUpdate201609Member 2020-01-01 2020-03-31 0001039065 us-gaap:AccountingStandardsUpdate201609Member 2019-07-01 2020-03-31 0001039065 us-gaap:AccountingStandardsUpdate201609Member 2019-01-01 2019-03-31 0001039065 us-gaap:AccountingStandardsUpdate201609Member 2018-07-01 2019-03-31 0001039065 osis:HealthcareDivisionMember 2020-01-01 2020-03-31 0001039065 osis:HealthcareDivisionMember 2019-07-01 2020-03-31 0001039065 osis:SecurityDivisionMember 2019-07-01 2020-03-31 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2019-07-01 2020-03-31 0001039065 osis:HealthcareDivisionMember 2019-07-01 2020-03-31 0001039065 osis:SecurityDivisionMember 2020-03-31 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2020-03-31 0001039065 osis:HealthcareDivisionMember 2020-03-31 0001039065 osis:SecurityDivisionMember 2019-06-30 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2019-06-30 0001039065 osis:HealthcareDivisionMember 2019-06-30 0001039065 us-gaap:PatentsMember 2019-07-01 2020-03-31 0001039065 us-gaap:DevelopedTechnologyRightsMember 2019-07-01 2020-03-31 0001039065 osis:CustomerRelationshipsOrderOrProductionBacklogMember 2019-07-01 2020-03-31 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-03-31 0001039065 us-gaap:PatentsMember 2020-03-31 0001039065 us-gaap:DevelopedTechnologyRightsMember 2020-03-31 0001039065 osis:CustomerRelationshipsOrderOrProductionBacklogMember 2020-03-31 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-06-30 0001039065 us-gaap:PatentsMember 2019-06-30 0001039065 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0001039065 osis:CustomerRelationshipsOrderOrProductionBacklogMember 2019-06-30 0001039065 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2020-03-31 0001039065 us-gaap:EmployeeStockOptionMember 2019-07-01 2020-03-31 0001039065 us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0001039065 us-gaap:EmployeeStockOptionMember 2020-03-31 0001039065 osis:ConvertibleSeniorNotesDue2022Member 2017-02-28 0001039065 osis:ConvertibleSeniorNotesDue2022Member 2019-06-30 0001039065 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-07-01 2020-03-31 0001039065 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-07-01 2020-03-31 0001039065 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-07-01 2020-03-31 0001039065 us-gaap:ServiceMember 2020-01-01 2020-03-31 0001039065 us-gaap:ProductMember 2020-01-01 2020-03-31 0001039065 us-gaap:ServiceMember 2019-07-01 2020-03-31 0001039065 us-gaap:ProductMember 2019-07-01 2020-03-31 0001039065 us-gaap:ServiceMember 2019-01-01 2019-03-31 0001039065 us-gaap:ProductMember 2019-01-01 2019-03-31 0001039065 us-gaap:ServiceMember 2018-07-01 2019-03-31 0001039065 us-gaap:ProductMember 2018-07-01 2019-03-31 0001039065 osis:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001039065 osis:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2020-03-31 0001039065 osis:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2020-03-31 0001039065 osis:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001039065 osis:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2019-06-30 0001039065 osis:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2019-03-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-03-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-12-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-06-30 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-03-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-12-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-06-30 0001039065 2019-03-31 0001039065 2018-06-30 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-01-01 2020-03-31 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-07-01 2020-03-31 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-01-01 2019-03-31 0001039065 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-07-01 2019-03-31 0001039065 osis:HealthcareDivisionMember 2018-07-01 2019-03-31 0001039065 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001039065 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001039065 osis:CxrLimitedMember 2020-03-31 0001039065 osis:OptoelectronicsSolutionsBusinessMember 2020-02-29 0001039065 osis:PrivatelyHeldServicesCompanyMember 2018-08-31 0001039065 osis:OptoelectronicsSolutionsBusinessMember 2018-07-31 2018-07-31 0001039065 us-gaap:CorporateMember 2020-01-01 2020-03-31 0001039065 osis:SecurityDivisionMember 2020-01-01 2020-03-31 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2020-01-01 2020-03-31 0001039065 us-gaap:CorporateMember 2019-07-01 2020-03-31 0001039065 osis:SecurityDivisionMember 2019-07-01 2020-03-31 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2019-07-01 2020-03-31 0001039065 osis:OptoelectronicsAndManufacturingDivisionMember 2018-07-01 2019-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2020-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2020-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2020-03-31 0001039065 us-gaap:IntersegmentEliminationMember 2020-03-31 0001039065 us-gaap:CorporateNonSegmentMember 2020-03-31 0001039065 us-gaap:OperatingSegmentsMember osis:SecurityDivisionMember 2019-06-30 0001039065 us-gaap:OperatingSegmentsMember osis:OptoelectronicsAndManufacturingDivisionMember 2019-06-30 0001039065 us-gaap:OperatingSegmentsMember osis:HealthcareDivisionMember 2019-06-30 0001039065 us-gaap:IntersegmentEliminationMember 2019-06-30 0001039065 us-gaap:CorporateNonSegmentMember 2019-06-30 0001039065 osis:ConvertibleSeniorNotesDue2022Member 2020-01-01 2020-03-31 0001039065 osis:ConvertibleSeniorNotesDue2022Member 2019-07-01 2020-03-31 0001039065 osis:ConvertibleSeniorNotesDue2022Member 2019-01-01 2019-03-31 0001039065 osis:ConvertibleSeniorNotesDue2022Member 2018-07-01 2019-03-31 0001039065 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001039065 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001039065 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001039065 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2020-03-31 0001039065 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2020-03-31 0001039065 us-gaap:CostOfSalesMember 2019-07-01 2020-03-31 0001039065 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0001039065 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001039065 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0001039065 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2019-03-31 0001039065 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2019-03-31 0001039065 us-gaap:CostOfSalesMember 2018-07-01 2019-03-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001039065 us-gaap:RetainedEarningsMember 2019-07-01 2020-03-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-07-01 2020-03-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2020-03-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001039065 us-gaap:RetainedEarningsMember 2018-07-01 2019-03-31 0001039065 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-07-01 2019-03-31 0001039065 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2019-03-31 0001039065 srt:MinimumMember osis:PerformanceBasedRestrictedStockUnitsMember 2019-07-01 2020-03-31 0001039065 srt:MaximumMember osis:PerformanceBasedRestrictedStockUnitsMember 2019-07-01 2020-03-31 0001039065 us-gaap:RestrictedStockUnitsRSUMember osis:IncentiveAwardPlan2012Member 2019-07-01 2020-03-31 0001039065 2020-01-01 2020-03-31 0001039065 us-gaap:FacilityClosingMember 2019-07-01 2020-03-31 0001039065 us-gaap:EmployeeSeveranceMember 2019-07-01 2020-03-31 0001039065 us-gaap:AcquisitionRelatedCostsMember 2019-07-01 2020-03-31 0001039065 osis:ChargesRelatedToLitigationMember 2019-07-01 2020-03-31 0001039065 us-gaap:RevolvingCreditFacilityMember 2020-03-31 0001039065 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2020-03-31 0001039065 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001039065 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001039065 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001039065 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001039065 2020-01-01 2020-03-31 0001039065 2019-01-01 2019-03-31 0001039065 2018-07-01 2019-03-31 0001039065 osis:ConvertibleSeniorNotesDue2022Member 2020-03-31 0001039065 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2020-03-31 0001039065 2020-03-31 0001039065 2019-06-30 0001039065 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-07-01 2020-03-31 0001039065 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001039065 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2020-03-31 0001039065 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2020-03-31 0001039065 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0001039065 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2019-06-30 0001039065 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2019-03-31 0001039065 osis:OptoelectronicsSolutionsBusinessMember 2020-02-01 2020-02-29 0001039065 osis:PrivatelyHeldServicesCompanyMember 2018-08-01 2018-08-31 0001039065 2020-04-28 0001039065 2019-07-01 2020-03-31 xbrli:shares iso4217:USD osis:customer xbrli:pure iso4217:USD xbrli:shares osis:item osis:segment

Table of Contents

​

​

​

UNITED STATES
SEC URITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 10-Q

​

(Mark One)

​

| ⌧ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the quarterly period ended March 31, 2020

​

OR

​

| ◻ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the transition period from to

​

Commission File Number 000-23125

​

OSI SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

​

​

Delaware |  | 33-0238801
(State or other jurisdiction of incorporation or organization) | ​ | (I.R.S. Employer Identification No.)

​

12525 Chadron Avenue

Hawthorne, California 90250

(Address of principal executive offices) (Zip Code)

​

(310) 978-0516

(Registrant’s telephone number, including area code)

​

N/A

(Former name, former address and former fiscal year, if changed since last report)

​

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.001 par value | OSIS | The NASDAQ Global Select Market

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ☐

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ☐

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

Large accelerated filer ☒ |  | Accelerated filer ☐
​ | ​ | ​
Non-accelerated filer ☐ | ​ | Smaller reporting company ☐
​ | ​ | ​
​ | ​ | Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

​

As of April 28, 2020, there were 18,011,235 shares of the registrant’s common stock outstanding.

​

​

​

​

Table of Contents

OSI SYSTEMS, INC.

INDEX

​ | ​ |
​ | ​ | PAGE
​ | ​ | ​
PART I — FINANCIAL INFORMATION | 3
​ | ​ | ​
Item 1 — | Financial Statements (Unaudited) | 3
​ | Condensed Consolidated Balance Sheets at June 30, 2019 and M arch 31, 2020 | 3
​ | Condensed Consolidated Statements of Operations for the three and nine months ended March 31, 2019 and 2020 | 4
​ | Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended March 31, 2019 and 2020 | 5
​ | Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended March 31, 2019 and 2020 | 6
​ | Condensed Consolidated Statements of Cash Flows for the nine months ended March 31, 2019 and 2020 | 8
​ | Notes to Condensed Consolidated Financial Statements | 9
Item 2 — | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 26
Item 3 — | Quantitative and Qualitative Disclosures about Market Risk | 33
Item 4 — | Controls and Procedures | 33
​ | ​ | ​
PART II — OTHER INFORMATION | 34
Item 1 — | Legal Proceedings | 34
Item 1A — | Risk Factors | 34
Item 2 — | Unregistered Sales of Equity Securities and Use of Proceeds | 35
Item 3 — | Defaults Upon Senior Securities | 35
Item 4 — | Mine Safety Disclosures | 35
Item 5 — | Other Information | 35
Item 6 — | Exhibits | 36
Signatures | ​ | 37

​

2

Table of Contents

PART I—FINANCIAL INFORMATION

​

ITEM 1. FINANCIAL STATEMENTS

​

OSI SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(amounts in thousands, except share amounts and par value)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | March 31,
​ |  | 2019 |  | 2020
ASSETS | ​ | ​ | ​ | ​ | ​ | ​
CURRENT ASSETS: | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | $ | 96,316 | ​ | $ | 101,026
Accounts receivable, net | ​ |  | 238,440 | ​ |  | 257,505
Inventories | ​ |  | 273,711 | ​ |  | 241,317
Prepaid expenses and other current assets | ​ |  | 32,432 | ​ |  | 38,522
Total current assets | ​ |  | 640,899 | ​ |  | 638,370
Property and equipment, net | ​ |  | 127,385 | ​ |  | 128,518
Goodwill | ​ |  | 307,108 | ​ |  | 308,639
Intangible assets, net | ​ |  | 132,954 | ​ |  | 129,471
Other assets | ​ |  | 56,518 | ​ |  | 81,596
Total assets | ​ | $ | 1,264,864 | ​ | $ | 1,286,594
​ | ​ | ​ | ​ | ​ | ​ | ​
LIABILITIES AND STOCKHOLDERS’ EQUITY | ​ | ​ | ​ | ​ | ​ | ​
CURRENT LIABILITIES: | ​ | ​ | ​ | ​ | ​ | ​
Bank lines of credit | ​ | $ | 88,000 | ​ | $ | 95,000
Current portion of long-term debt | ​ |  | 804 | ​ |  | 903
Accounts payable | ​ |  | 93,500 | ​ |  | 103,797
Accrued payroll and related expenses | ​ |  | 43,521 | ​ |  | 37,577
Advances from customers | ​ |  | 43,227 | ​ |  | 32,968
Other accrued expenses and current liabilities | ​ |  | 112,956 | ​ |  | 105,717
Total current liabilities | ​ |  | 382,008 | ​ |  | 375,962
Long-term debt | ​ |  | 257,752 | ​ |  | 264,777
Deferred income taxes | ​ |  | 7,979 | ​ |  | 6,881
Other long-term liabilities | ​ |  | 65,398 | ​ |  | 86,698
Total liabilities | ​ |  | 713,137 | ​ |  | 734,318
Commitments and contingencies (Note 9) | ​ | ​ | ​ | ​ | ​ | ​
STOCKHOLDERS’ EQUITY: | ​ | ​ | ​ | ​ | ​ | ​
Preferred stock, $0.001 par value—10,000,000 shares authorized; no shares issued or outstanding | ​ |  | — | ​ |  | —
Common stock, $0.001 par value—100,000,000 shares authorized; issued and outstanding, 18,167,020 shares at June 30, 2019 and 18,010,625 shares at March 31, 2020 | ​ |  | 168,913 | ​ |  | 116,872
Retained earnings | ​ |  | 399,541 | ​ |  | 460,828
Accumulated other comprehensive loss | ​ |  | (16,727) | ​ |  | (25,424)
Total stockholders’ equity | ​ |  | 551,727 | ​ |  | 552,276
Total liabilities and stockholders’ equity | ​ | $ | 1,264,864 | ​ | $ | 1,286,594

​

See accompanying notes to condensed consolidated financial statements.

​

3

Table of Contents

OSI SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(amounts in thousands, except per share data)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | Nine Months Ended March 31, | ​
​ |  | 2019 |  | 2020 |  | 2019 |  | 2020 |
Net revenues: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Products | ​ | $ | 224,778 | ​ | $ | 213,257 | ​ | $ | 632,660 | ​ | $ | 646,790 | ​
Services | ​ |  | 79,506 | ​ |  | 79,626 | ​ |  | 241,078 | ​ |  | 242,287 | ​
Total net revenues | ​ |  | 304,284 | ​ |  | 292,883 | ​ |  | 873,738 | ​ |  | 889,077 | ​
Cost of goods sold: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Products | ​ |  | 147,939 | ​ |  | 141,069 | ​ |  | 423,441 | ​ |  | 436,120 | ​
Services | ​ |  | 45,029 | ​ |  | 42,707 | ​ |  | 132,724 | ​ |  | 133,866 | ​
Total cost of goods sold | ​ |  | 192,968 | ​ |  | 183,776 | ​ |  | 556,165 | ​ |  | 569,986 | ​
Gross profit | ​ |  | 111,316 | ​ |  | 109,107 | ​ |  | 317,573 | ​ |  | 319,091 | ​
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Selling, general and administrative | ​ |  | 67,278 | ​ |  | 65,576 | ​ |  | 196,082 | ​ |  | 191,655 | ​
Research and development | ​ |  | 13,695 | ​ |  | 15,358 | ​ |  | 40,253 | ​ |  | 44,485 | ​
Impairment, restructuring and other charges (benefit), net | ​ |  | (1,777) | ​ |  | 4,548 | ​ |  | 1,154 | ​ |  | 1,520 | ​
Total operating expenses | ​ |  | 79,196 | ​ |  | 85,482 | ​ |  | 237,489 | ​ |  | 237,660 | ​
Income from operations | ​ |  | 32,120 | ​ |  | 23,625 | ​ |  | 80,084 | ​ |  | 81,431 | ​
Interest and other expense, net | ​ |  | (5,595) | ​ |  | (4,706) | ​ |  | (16,546) | ​ |  | (14,286) | ​
Income before income taxes | ​ |  | 26,525 | ​ |  | 18,919 | ​ |  | 63,538 | ​ |  | 67,145 | ​
(Provision) benefit for income taxes | ​ |  | (6,899) | ​ |  | 639 | ​ |  | (15,403) | ​ |  | (5,858) | ​
Net income | ​ | $ | 19,626 | ​ | $ | 19,558 | ​ | $ | 48,135 | ​ | $ | 61,287 | ​
Earnings per share: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | $ | 1.09 | ​ | $ | 1.08 | ​ | $ | 2.66 | ​ | $ | 3.36 | ​
Diluted | ​ | $ | 1.05 | ​ | $ | 1.06 | ​ | $ | 2.58 | ​ | $ | 3.28 | ​
Shares used in per share calculation: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ |  | 18,079 | ​ |  | 18,182 | ​ |  | 18,085 | ​ |  | 18,251 | ​
Diluted | ​ |  | 18,671 | ​ |  | 18,513 | ​ |  | 18,678 | ​ |  | 18,693 | ​

​

See accompanying notes to condensed consolidated financial statements.

​

4

Table of Contents

OSI SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

(amounts in thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | Nine Months Ended March 31,
​ |  | 2019 |  | 2020 |  | 2019 |  | 2020
Net income | ​ | $ | 19,626 | ​ | $ | 19,558 | ​ | $ | 48,135 | ​ | $ | 61,287
Other comprehensive income (loss): | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency translation adjustment | ​ |  | 1,521 | ​ |  | (8,314) | ​ |  | (2,694) | ​ |  | (8,726)
Other | ​ |  | 7 | ​ |  | 10 | ​ |  | 22 | ​ |  | 29
Other comprehensive income (loss) | ​ | ​ | 1,528 | ​ | ​ | (8,304) | ​ | ​ | (2,672) | ​ | ​ | (8,697)
Comprehensive income | ​ | $ | 21,154 | ​ | $ | 11,254 | ​ | $ | 45,463 | ​ | $ | 52,590

​

See accompanying notes to condensed consolidated financial statements.

​

5

Table of Contents

OSI SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

(amounts in thousands, except share data)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2019
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | Common Stock | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ |  | Number of |  | ​ | ​ |  | Retained |  | Comprehensive |  | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Earnings | ​ | Loss | ​ | Total
Balance—December 31, 2018 |  | 18,020,907 | ​ | $ | 151,926 | ​ | $ | 363,254 | ​ | $ | (18,984) | ​ | $ | 496,196
Exercise of stock options |  | 58,613 | ​ | ​ | 1,196 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,196
Vesting of RSUs |  | 1,219 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Shares issued under employee stock purchase program |  | 36,020 | ​ | ​ | 2,160 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,160
Stock-based compensation expense |  | — | ​ | ​ | 5,888 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,888
Taxes paid related to net share settlement of equity awards |  | (15,918) | ​ | ​ | (786) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (786)
Net income |  | — | ​ | ​ | — | ​ | ​ | 19,626 | ​ | ​ | — | ​ | ​ | 19,626
Other comprehensive income |  | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,528 | ​ | ​ | 1,528
Balance—March 31, 2019 | ​ | 18,100,841 | ​ | $ | 160,384 | ​ | $ | 382,880 | ​ | $ | (17,456) | ​ | $ | 525,808

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2020
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | Common Stock | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ |  | Number of |  | ​ | ​ |  | Retained |  | Comprehensive |  | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Earnings | ​ | Loss | ​ | Total
Balance—December 31, 2019 | ​ | 18,267,574 | ​ | $ | 133,566 | ​ | $ | 441,270 | ​ | $ | (17,120) | ​ | $ | 557,716
Exercise of stock options | ​ | 1,041 | ​ | ​ | 80 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 80
Vesting of RSUs | ​ | 1,671 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Shares issued under employee stock purchase program | ​ | 36,758 | ​ | ​ | 2,221 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,221
Stock-based compensation expense | ​ | — | ​ | ​ | 5,837 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,837
Repurchase of common stock | ​ | (295,833) | ​ | ​ | (24,781) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (24,781)
Taxes paid related to net share settlement of equity awards | ​ | (586) | ​ | ​ | (51) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (51)
Net income | ​ | — | ​ | ​ | — | ​ | ​ | 19,558 | ​ | ​ | — | ​ | ​ | 19,558
Other comprehensive loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (8,304) | ​ | ​ | (8,304)
Balance—March 31, 2020 |  | 18,010,625 | ​ | $ | 116,872 | ​ | $ | 460,828 | ​ | $ | (25,424) | ​ | $ | 552,276

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31, 2019
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | Common Stock | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ |  | Number of |  | ​ | ​ |  | Retained |  | Comprehensive |  | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Earnings | ​ | Loss | ​ | Total
Balance—June 30, 2018 |  | 18,032,374 | ​ | $ | 169,475 | ​ | $ | 334,745 | ​ | $ | (14,784) | ​ | $ | 489,436
Exercise of stock options |  | 108,008 | ​ |  | 1,985 | ​ |  | — | ​ |  | — | ​ |  | 1,985
Vesting of RSUs |  | 357,924 | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | —
Shares issued under employee stock purchase program |  | 75,313 | ​ |  | 4,180 | ​ |  | — | ​ |  | — | ​ |  | 4,180
Stock-based compensation expense |  | — | ​ |  | 19,514 | ​ |  | — | ​ |  | — | ​ |  | 19,514
Repurchase of common stock | ​ | (288,316) | ​ | ​ | (21,029) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (21,029)
Taxes paid related to net share settlement of equity awards |  | (184,462) | ​ |  | (13,741) | ​ |  | — | ​ |  | — | ​ |  | (13,741)
Net income |  | — | ​ |  | — | ​ |  | 48,135 | ​ |  | — | ​ |  | 48,135
Other comprehensive loss |  | — | ​ |  | — | ​ |  | — | ​ |  | (2,672) | ​ |  | (2,672)
Balance—March 31, 2019 | ​ | 18,100,841 | ​ | $ | 160,384 | ​ | $ | 382,880 | ​ | $ | (17,456) | ​ | $ | 525,808

​

6

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31, 2020
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | Common Stock | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ |  | Number of |  | ​ | ​ |  | Retained |  | Comprehensive |  | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Earnings | ​ | Loss | ​ | Total
Balance—June 30, 2019 |  | 18,167,020 | ​ | $ | 168,913 | ​ | $ | 399,541 | ​ | $ | (16,727) | ​ | $ | 551,727
Exercise of stock options |  | 201,003 | ​ |  | 4,112 | ​ |  | — | ​ |  | — | ​ |  | 4,112
Vesting of RSUs |  | 388,756 | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | —
Shares issued under employee stock purchase program |  | 71,595 | ​ |  | 4,286 | ​ |  | — | ​ |  | — | ​ |  | 4,286
Stock-based compensation expense |  | — | ​ |  | 18,097 | ​ |  | — | ​ |  | — | ​ |  | 18,097
Repurchase of common stock | ​ | (562,707) | ​ | ​ | (51,775) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (51,775)
Taxes paid related to net share settlement of equity awards |  | (255,042) | ​ |  | (26,761) | ​ |  | — | ​ |  | — | ​ |  | (26,761)
Net income |  | — | ​ |  | — | ​ |  | 61,287 | ​ |  | — | ​ |  | 61,287
Other comprehensive loss |  | — | ​ |  | — | ​ |  | — | ​ |  | (8,697) | ​ |  | (8,697)
Balance—March 31, 2020 | ​ | 18,010,625 | ​ | $ | 116,872 | ​ | $ | 460,828 | ​ | $ | (25,424) | ​ | $ | 552,276

​

See accompanying notes to condensed consolidated financial statements.

​

7

Table of Contents

OSI SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(amounts in thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31,
​ |  | 2019 |  | 2020
CASH FLOWS FROM OPERATING ACTIVITIES | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | $ | 48,135 | ​ | $ | 61,287
Adjustments to reconcile net income to net cash provided by operating activities, net of effects from acquisitions: | ​ | ​ | ​ | ​ | ​ | ​
Depreciation and amortization | ​ |  | 42,401 | ​ |  | 37,807
Stock-based compensation expense | ​ |  | 19,514 | ​ |  | 18,097
Deferred income taxes | ​ | ​ | (3,220) | ​ | ​ | (50)
Amortization of debt discount and issuance costs | ​ | ​ | 6,733 | ​ | ​ | 6,984
Other | ​ |  | 1,617 | ​ |  | 2,778
Changes in operating assets and liabilities—net of business acquisitions: | ​ | ​ | ​ | ​ | ​ | ​
Accounts receivable | ​ |  | (5,967) | ​ |  | (23,945)
Inventories | ​ |  | 16,232 | ​ |  | 31,094
Prepaid expenses and other assets | ​ |  | (6,620) | ​ |  | (17,092)
Accounts payable | ​ | ​ | (20,265) | ​ | ​ | 10,243
Accrued payroll and related expenses | ​ | ​ | (4,008) | ​ | ​ | (5,655)
Advances from customers | ​ |  | 4,258 | ​ |  | (9,846)
Other | ​ |  | (11,066) | ​ |  | (6,149)
Net cash provided by operating activities | ​ |  | 87,744 | ​ |  | 105,553
CASH FLOWS FROM INVESTING ACTIVITIES | ​ | ​ | ​ | ​ | ​ | ​
Acquisition of property and equipment | ​ |  | (20,905) | ​ |  | (16,062)
Acquisition of businesses, net of cash acquired | ​ |  | (18,271) | ​ |  | (3,521)
Acquisition of intangible and other assets | ​ |  | (1,657) | ​ |  | (8,764)
Net cash used in investing activities | ​ |  | (40,833) | ​ |  | (28,347)
CASH FLOWS FROM FINANCING ACTIVITIES | ​ | ​ | ​ | ​ | ​ | ​
Net borrowings on bank lines of credit | ​ |  | 11,000 | ​ |  | 7,000
Proceeds from long-term debt | ​ |  | 1,019 | ​ |  | 592
Payments on long-term debt | ​ |  | (1,880) | ​ |  | (723)
Proceeds from exercise of stock options and employee stock purchase plan | ​ |  | 6,165 | ​ |  | 8,398
Payments of contingent consideration | ​ | ​ | (4,797) | ​ | ​ | (5,265)
Repurchases of common stock | ​ |  | (21,029) | ​ |  | (51,775)
Taxes paid related to net share settlement of equity awards | ​ |  | (13,741) | ​ |  | (26,761)
Net cash used in financing activities | ​ |  | (23,263) | ​ |  | (68,534)
Effect of exchange rate changes on cash | ​ |  | (813) | ​ |  | (3,962)
Net change in cash and cash equivalents | ​ |  | 22,835 | ​ |  | 4,710
Cash and cash equivalents—beginning of period | ​ |  | 84,814 | ​ |  | 96,316
Cash and cash equivalents—end of period | ​ | $ | 107,649 | ​ | $ | 101,026
Supplemental disclosure of cash flow information: | ​ | ​ | ​ | ​ | ​ | ​
Cash paid, net during the period for: | ​ | ​ | ​ | ​ | ​ | ​
Interest | ​ | $ | 9,394 | ​ | $ | 6,773
Income taxes | ​ | $ | 28,233 | ​ | $ | 16,141

​

See accompanying notes to condensed consolidated financial statements.

​

8

Table of Contents

OSI SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

​

1. Basis of Presentation

​

Basis of Presentation

​

The condensed consolidated financial statements include the accounts of OSI Systems, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and in conjunction with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures required for annual financial statements have been condensed or excluded in accordance with SEC rules and regulations applicable to interim unaudited financial statements. Accordingly, the condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited annual financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments of a normal and recurring nature that are considered necessary for a fair presentation of the results for the interim periods presented. These unaudited condensed consolidated financial statements and the accompanying notes should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC. The results of operations for the three and nine months ended March 31, 2020 are not necessarily indicative of the operating results to be expected for the full 2020 fiscal year or any future periods.

​

Use of Estimates

​

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and costs of sales during the reporting period. The most significant of these estimates and assumptions for our company relate to contract revenue, profit and loss recognition, fair values of assets acquired and liabilities assumed in business combinations, values for inventories reported at lower of cost or net realizable value, stock-based compensation expense, income taxes, accrued warranty costs, and the recoverability, useful lives and valuation of recorded amounts of long-lived assets, identifiable intangible assets and goodwill. Changes in estimates are reflected in the periods during which they become known. Due to the inherent uncertainty involved in making estimates, our actual amounts reported in future periods could differ materially from these estimates.

​

Earnings Per Share Computations

​

We compute basic earnings per share by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period. We compute diluted earnings per share by dividing net income available to common stockholders by the sum of the weighted average number of common shares and dilutive potential common shares outstanding during the period. Potential common shares consist of the shares issuable upon the exercise of stock options and restricted stock unit awards under the treasury stock method. The underlying equity component of the 1.25% convertible senior notes due 2022 (the “Notes”) discussed in Note 6 to the condensed consolidated financial statements will not have a net impact on diluted earnings per share unless the average price of our common stock exceeds the conversion price because the principal amount of the Notes is intended to be settled in cash upon conversion. There was no dilutive effect of the Notes for the three and nine months ended March 31, 2019 and 2020.

​

9

Table of Contents

The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share amounts):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | Nine Months Ended March 31,
​ |  | 2019 |  | 2020 |  | 2019 |  | 2020
Net income available to common stockholders | ​ | $ | 19,626 | ​ | $ | 19,558 | ​ | $ | 48,135 | ​ | $ | 61,287
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average shares outstanding—basic | ​ |  | 18,079 | ​ |  | 18,182 | ​ |  | 18,085 | ​ |  | 18,251
Dilutive effect of equity awards | ​ |  | 592 | ​ |  | 331 | ​ |  | 593 | ​ |  | 442
Weighted average shares outstanding—diluted | ​ |  | 18,671 | ​ |  | 18,513 | ​ |  | 18,678 | ​ |  | 18,693
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic earnings per share | ​ | $ | 1.09 | ​ | $ | 1.08 | ​ | $ | 2.66 | ​ | $ | 3.36
Diluted earnings per share | ​ | $ | 1.05 | ​ | $ | 1.06 | ​ | $ | 2.58 | ​ | $ | 3.28
Shares excluded from diluted earnings per share due to their anti-dilutive effect | ​ | ​ | 44 | ​ | ​ | 145 | ​ | ​ | 46 | ​ | ​ | 100

​

Cash and Cash Equivalents

​

We consider all highly liquid investments with maturities of three months or less as of the acquisition date to be cash equivalents.

​

Our cash and cash equivalents totaled $101.0 million at March 31, 2020. Of this amount, approximately 64% was held by our foreign subsidiaries and subject to repatriation tax considerations. These foreign funds were held primarily by our subsidiaries in Singapore, the United Kingdom, Malaysia, Mexico, Canada and Australia and to a lesser extent in Germany, India, and Albania among other countries. We have cash holdings in financial institutions that exceed insured limits for such institutions; however, we mitigate this risk by utilizing high credit quality financial institutions throughout the world.

​

Fair Value of Financial Instruments

​

Our financial instruments consist primarily of cash and cash equivalents, insurance company contracts, accounts receivable, accounts payable and debt instruments. The carrying values of financial instruments, other than long-term debt instruments, are representative of their fair values due to their short-term maturities. The carrying values of our long-term debt instruments are considered to approximate their fair values, as the interest rates of these instruments are variable or comparable to current rates for financing available to us.

​

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The "Level 1" category includes assets and liabilities measured at quoted prices in active markets for identical assets and liabilities. The “Level 2" category includes assets and liabilities measured from observable inputs other than quoted market prices. The "Level 3" category includes assets and liabilities for which valuation inputs are unobservable and significant to the fair value measurement. As of June 30, 2019 and March 31, 2020, there were no assets in the "Level 1" and "Level 3" categories. Our contingent payment obligations related to acquisitions, which are further discussed in Note 9 to the condensed consolidated financial statements, are in the “Level 3” category for valuation purposes.

​

The fair values of our financial assets and liabilities are categorized as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, 2019 | ​ | March 31, 2020
​ |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Insurance company contracts |  | $ | — |  | $ | 35,899 |  | $ | — |  | $ | 35,899 |  | $ | — | ​ | $ | 32,441 |  | $ | — |  | $ | 32,441
Liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Contingent consideration | ​ | $ | — | ​ | $ | — | ​ | $ | 16,577 | ​ | $ | 16,577 | ​ | $ | — | ​ | $ | — | ​ | $ | 13,206 | ​ | $ | 13,206

​

10

Table of Contents

Goodwill Impairment

​

Goodwill represents the excess purchase price over the estimated fair value of the assets acquired and liabilities assumed in a business combination. Goodwill is allocated to our segments based on the nature of the product line of the acquired business. The carrying value of goodwill is not amortized, but is annually tested for impairment during our second fiscal quarter and more frequently if there is an indicator of impairment. We assess qualitative factors of each of our three reporting units to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The assessments conducted as of December 31, 2019 indicated that it is not more likely than not that the fair values of all three reporting units are less than their carrying amounts, including goodwill. Thus, we have determined that there is no goodwill impairment for any of the three reporting units.

​

Revenue Recognition

​

We recognize revenue under Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”), which superseded all prior revenue recognition methods and industry-specific guidance. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of control for promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the revenue recognition principles, an entity is required to identify the contract(s) with a customer, identify the performance obligations, determine the transaction price, allocate the transaction price to the performance obligations and recognize revenue as the performance obligations are satisfied (i.e., either over time or at a point in time). ASC 606 further requires that companies disclose sufficient information to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.

​

Product Sales. We recognize revenue from sales of products upon shipment or delivery when control of the product transfers to the customer, depending on the terms of each sale, and when collection is probable. In the circumstance where terms of a product sale include subjective customer acceptance criteria, revenue is deferred until we have achieved the customer acceptance criteria unless the acceptance criteria are perfunctory or inconsequential. We generally offer customers payment terms of less than one year. In cases when payment terms extend beyond one year, we consider whether the contract has a significant financing component.

​

Service Revenue. Revenue from services includes installation and implementation of products and turnkey security screening services and after-market services. Generally, revenue from services is recognized over time as the services are performed. Revenues from out of warranty service maintenance contracts are recognized ratably over the respective terms of such contracts. Deferred revenue for such services arises from payments received from customers for services not yet performed.

​

Contract Revenue. Sales agreements with customers can be project specific, cover a period of time, and can be renewable periodically. The contracts may contain terms and conditions with respect to payment, delivery, installation, services, warranty and other rights. In certain instances, we consider an accepted customer order, governed by a master sales agreement, to be the contract with the customer when legal rights and obligations exist. Contracts with customers may include the sale of products and services, as discussed in the paragraphs above. In certain instances, contracts can contain multiple performance obligations as discussed in the paragraph below. According to the terms of a sale contract, we may receive consideration from a customer prior to transferring goods to the customer, and we record these prepayments as a contract liability. We also record deferred revenue, typically related to service contacts, when consideration is received before the services have been performed. We recognize contract liabilities and deferred revenue as net sales after all revenue recognition criteria are met.

​

When determining revenue recognition for contracts, we make judgments based on our understanding of the obligations in each contract. We determine whether or not customer acceptance criteria are perfunctory or inconsequential. The determination of whether or not customer acceptance terms are perfunctory or inconsequential impacts the amount and timing of revenue recognition. Critical judgments also include estimates of warranty reserves, which are established based on historical experience and knowledge of the product under warranty.

​

Multiple Performance Obligations. Certain agreements with customers include the sale of capital equipment involving multiple elements that may include civil works to prepare a site for the installation of equipment, manufacture and delivery of equipment, installation and integration of equipment, training of customer personnel to operate the equipment and after-market service of the equipment. We generally separate multiple elements in a contract into separate performance obligations if those elements are distinct, both individually and in the context of the contract. If multiple promises comprise a series of distinct services which are substantially the same and have the same pattern of transfer, they are combined and accounted for as a single performance obligation.

​

11

Table of Contents

In cases where obligations in a contract are distinct and thus require separation into multiple performance obligations, revenue recognition guidance requires that contract consideration be allocated to each distinct performance obligation based on its relative standalone selling price. The value allocated to each performance obligation is then recognized as revenue when the revenue recognition criteria for each distinct obligation or bundle of obligations has been met.

​

The standalone selling price for each performance obligation is an amount that depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the good or service. When there is only one performance obligation associated with a contract, the entire amount of consideration is attributed to that obligation. When a contract contains multiple performance obligations the standalone selling price is first estimated using the observable price, which is generally a list price net of applicable discount or the price used to sell the good or service in similar circumstances. In circumstances when a selling price is not directly observable, we will estimate the standalone selling price using information available to us including our market assessment and expected cost plus margin.

​

The timetable for fulfilment of each of the distinct performance obligations can range from completion in a short amount of time and entirely within a single reporting period to completion over several reporting periods. The timing of revenue recognition for each performance obligation may be dependent upon several milestones, including physical delivery of equipment, completion of factory acceptance test, completion of site acceptance test, installation and connectivity of equipment, certification of training of personnel and, in the case of after-market service deliverables, the passage of time (typically evenly over the post-warranty period of the service deliverable).

​

We often provide a guarantee to support our performance under the contract which may contain one or more performance obligations. In the event that customers are permitted to terminate such arrangements, the underlying contract typically requires payment by the customer for deliverables and reimbursement of costs incurred through the date of termination.

​

We disaggregate revenue by reporting segment (Security, Optoelectronics and Manufacturing, and Healthcare) to depict the nature of revenue in a manner consistent with our business operations and to be consistent with other communications and public filings. Refer to Note 11 to our condensed consolidated financial statements for additional details of revenues by reporting segment.

​

Contract Assets and Liabilities. We enter into contracts to sell products and provide services, and we recognize contract assets and liabilities that arise from these transactions. We recognize revenue and corresponding accounts receivable according to ASC 606 and, at times, recognize revenue in advance of the time when contracts give us the right to invoice a customer. We may also receive consideration, per the terms of a contract, from customers prior to transferring goods to the customer. We record customer deposits as contract liabilities. Additionally, we may receive payments, most typically for service and warranty contracts, at the onset of the contract and before the services have been performed. In such instances, we record a deferred revenue liability. We recognize these contract liabilities as sales after all revenue recognition criteria are met.

​

Contract assets and liabilities were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, |  | March 31, |  | ​ | ​ |  | ​ |
Contract Assets: | ​ | 2019 | ​ | 2020 | ​ | Change | ​ | % Change |
Unbilled revenue | ​ | $ | 19,287 | ​ | $ | 34,706 | ​ | $ | 15,419 |  | 80 | %

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Contract Liabilities: |  | ​ |  | ​ |  | ​ |  | ​ |
Advances from customers | ​ | $ | 43,227 | ​ | $ | 32,968 | ​ | $ | (10,259) | ​ | (24) | %
Deferred revenue—current | ​ |  | 33,641 | ​ |  | 30,745 | ​ |  | (2,896) | ​ | (9) | %
Deferred revenue—long-term | ​ |  | 9,506 | ​ |  | 14,511 | ​ |  | 5,005 | ​ | 53 | %

​

Contract assets increased during the nine months ended March 31, 2020 primarily due to satisfaction of performance obligations for explosive detection systems and cargo and vehicle inspection systems in our Security division which have not yet been billed to customers. The net decrease in contract liabilities was primarily due to satisfaction of performance obligations and application of payments against customer billings on cargo and vehicle system contracts in our Security division.

​

12

Table of Contents

Remaining Performance Obligations. Remaining performance obligations related to ASC 606 represent the aggregate transaction price allocated to performance obligations under an original contract with a term greater than one year which are fully or partially unsatisfied at the end of the period. As of March 31, 2020, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $178.3 million. We expect to recognize revenue on approximately 70% of the remaining performance obligations over the next 12 months, and the remainder is expected to be recognized thereafter. During the nine months ended March 31, 2020, we recognized revenue of $70.3 million from contract liabilities existing at the beginning of the period.

​

Practical Expedients. In cases where we are responsible for shipping after the customer has obtained control of the goods, we have elected to treat the shipping activities as fulfillment activities rather than as a separate performance obligation. Additionally, we have elected to capitalize the cost to obtain a contract only if the period of amortization would be longer than one year. We only give consideration to whether a customer agreement has a financing component if the period of time between transfer of goods and services and customer payment is greater than one year.

​

Lease Accounting

​

Right of use (“ROU”) assets represent our right to use an underlying asset during the reasonably certain lease terms, and lease liabilities represent our obligation to make lease payments arising from the leases. We recognize ROU lease assets and lease liabilities at lease commencement on our consolidated balance sheet based on the present value of lease payments over the lease term using a discount rate determined based on our incremental borrowing rate since the rate implicit in each lease is not readily determinable. We elected the package of practical expedients, which permits us to not reassess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification of any expired or existing leases, and (3) any initial direct costs for any existing leases as of the effective date. We elected the practical expedient to account for each separate lease component of a contract and its associated non-lease components as a single lease component. We also elected the hindsight practical expedient, which allows us to use hindsight in determining the lease term. We do not record an ROU asset and corresponding lease liability for leases with an initial term of one year or less (“short-term leases”). The terms in our leases may include options to extend or terminate the lease. We recognize ROU assets and liabilities when it is reasonably certain that we will exercise those options. Judgment is required in our assessment as to whether renewal or termination options are reasonably certain to be exercised and factors such as contractual terms compared to current market rates and the importance of the facility and location to our operations, among others, are considered. Lease payments are made in accordance with the lease terms, and lease expense, including short-term lease expense, is recognized on a straight-line basis over the lease term.

​

We lease facilities and certain equipment under various operating lease agreements. The majority of our lease arrangements are comprised of fixed payments while certain of our other leases provide for periodic rent increases. Our leases may contain escalation clauses and renewal options. Most of the leases require us to pay for certain other costs such as common area maintenance and property taxes. Rent expense for leases with periodic rent increases or escalation clauses is recognized on a straight-line basis over the minimum lease term. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. We also have finance leases for fleet vehicles that are not material to the condensed consolidated financial statements.

​

The components of operating lease expense were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ |  | March 31, 2020 |  | March 31, 2020
Operating lease cost | ​ | $ | 2,525 | ​ | $ | 7,771
Variable lease cost |  | ​ | 237 | ​ | ​ | 551
Short-term lease cost |  | ​ | 350 | ​ | ​ | 745
​ | ​ | $ | 3,112 | ​ | $ | 9,067

​

13

Table of Contents

Supplemental balance sheet assets and liabilities related to operating leases were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​
​ |  | Balance Sheet Category |  | March 31, 2020
Operating lease ROU assets, net |  | Other assets | ​ | $ | 26,397
​ | ​ | ​ | ​ | ​ | ​
Operating lease liabilities, current portion |  | Other accrued expenses and current liabilities | ​ | $ | 8,118
Operating lease liabilities, long-term |  | Other long-term liabilities | ​ |  | 18,648
Total operating lease liabilities |  |  | ​ | $ | 26,766
​ | ​ | ​ | ​ | ​ | ​
Weighted average remaining lease term |  |  | ​ |  | 4.4 years
Weighted average discount rate |  |  | ​ |  | 4.3%

​

Supplemental cash flow information related to operating leases was as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ |  | March 31, 2020 |  | March 31, 2020
Cash paid for operating lease liabilities | ​ | $ | 2,466 | ​ | $ | 7,664
ROU assets obtained in exchange for new lease obligations | ​ | ​ | 2,239 | ​ |  | 3,718

​

Maturities of operating lease liabilities under ASC 842 (defined below) at March 31, 2020 were as follows (in thousands):

​

​ | ​ | ​ | ​
​ |  | March 31, 2020
Less than one year | ​ | $ | 9,036
1 – 2 years | ​ |  | 6,808
2 – 3 years | ​ |  | 4,318
3 – 4 years | ​ |  | 3,562
4 – 5 years | ​ |  | 2,529
Thereafter | ​ |  | 3,143
​ | ​ |  | 29,396
Less: Imputed interest | ​ |  | (2,630)
Total lease liabilities | ​ | $ | 26,766

​

Maturities of minimum operating lease liabilities under non-cancelable leases under ASC 840 (defined below) at June 30, 2019 were as follows (in thousands):

​

​ | ​ | ​ | ​
​ |  | June 30, 2019
Less than one year | ​ | $ | 9,802
1 – 2 years | ​ |  | 8,082
2 – 3 years | ​ |  | 5,473
3 – 4 years | ​ |  | 3,397
4 – 5 years | ​ |  | 2,954
Thereafter | ​ |  | 4,583
Total lease liabilities | ​ | $ | 34,291

​

Recently Adopted Accounting Pronouncement

​

Leases

​

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842) (“ASC 842”), which requires a lessee to recognize ROU assets and lease liabilities, initially measured at present value of the lease payments, on its balance sheet for leases and classified as either financing or operating leases. We adopted ASC 842 on July 1, 2019, using the modified retrospective method, and we elected the package of practical expedients provided in ASC 842. In accordance with ASC 842, we did not restate comparative periods and instead reported comparative prior year periods under ASC 840, “Leases.”

​

14

Table of Contents

The cumulative effect of the changes made to our July 1, 2019 consolidated condensed balance sheet for the adoption of the new lease standard was as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Balance at | ​ | Effect of Adoption | ​ | Balance at
Balance Sheet |  | June 30, 2019 |  | of ASC 842 |  | July 1, 2019
Assets |  | ​ | ​ |  | ​ |  |  | ​ |
Other assets | ​ | $ | 56,518 | ​ | $ | 30,066 | ​ | $ | 86,584
Liabilities | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
Other accrued expenses and current liabilities | ​ | $ | 112,956 | ​ | $ | 8,324 | ​ | $ | 121,280
Other long-term liabilities | ​ |  | 65,398 | ​ |  | 21,742 | ​ |  | 87,140

​

The adoption of the new lease accounting guidance did not have a material impact on the condensed consolidated statement of operations or the condensed consolidated statement of cash flows for the nine months ended March 31, 2020.

​

Recently Issued Accounting Pronouncements Not Yet Adopted

​

Income Taxes

​

In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 removes certain exceptions to the general principles of ASC 740, and is intended to improve consistency and simplify GAAP in several other areas of ASC 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for publicly-traded business entities for annual reporting periods beginning after December 15, 2020, and interim periods within those reporting periods. Early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the potential impact of adoption of this guidance on our consolidated financial statements.

​

Retirement Benefit Plans

​

In August 2018, the FASB issued authoritative guidance under ASU 2018-14, Compensation—Retirement Benefits—Defined Benefit Plans—General: Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans. This ASU eliminates requirements for certain disclosures and requires additional disclosures under defined benefit pension plans and other post-retirement plans. We are required to adopt this new guidance in the first quarter of fiscal 2021. We are currently evaluating the potential impact of the adoption of this guidance on our consolidated financial statements.

​

Intangibles

​

In August 2018, the FASB issued authoritative guidance under ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software: Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. This ASU requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software and deferred over the non-cancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. We are required to adopt this new guidance in the first quarter of fiscal 2021. We are currently evaluating the potential impact of adoption of this guidance on our consolidated financial statements.

​

2. Business Combinations

​

Under ASC 805, Business Combinations, the acquisition method of accounting requires us to record assets acquired less liabilities assumed in an acquisition at their estimated fair values at the date of acquisition. Any excess of the total estimated purchase consideration over the estimated fair value of the assets acquired less liabilities assumed should be recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired customers, acquired technology, trade names, useful lives and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. We may record adjustments to the assets acquired and liabilities assumed, with corresponding adjustments to goodwill, during the one-year post-acquisition measurement period as additional information becomes available. Upon the conclusion of the measurement period, any subsequent adjustments are reflected in reported earnings.

​

15

Table of Contents

Fiscal Year 2020 Business Acquisition

​

In February 2020, we (through our Optoelectronics and Manufacturing division) acquired a privately-held manufacturing business for $3.35 million, plus up to $1.65 million in potential contingent consideration, which may be earned over a three-year period. The acquisition was financed with cash on hand. The goodwill recognized for this business is deductible for income tax purposes.

​

Fiscal Year 2019 Business Acquisitions

​

In January 2019, we (through our Security division) acquired a privately held sales and services company. The acquisition was financed with cash on hand and was in an amount determined to be insignificant by management.

​

In August 2018, we (through our Security division) acquired a privately held services company for approximately $0.8 million, plus up to approximately $5 million in potential contingent consideration, which may be earned over the five-year period after the acquisition. The acquisition was financed with cash on hand. The goodwill recognized for this business is not deductible for income tax purposes.

​

In July 2018, we (through our Optoelectronics and Manufacturing division) acquired an optoelectronics solutions business for $17.5 million. The acquisition was financed with cash on hand and borrowings under our revolving bank line of credit. The goodwill recognized for this business is deductible for income tax purposes.

​

These business acquisitions, individually and in the aggregate, were not material to our consolidated financial statements. Accordingly, pro-forma historical results of operations related to these businesses have not been presented.

​

3. Balance Sheet Details

​

The following tables provide details of selected balance sheet accounts (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | March 31,
Accounts receivable, net |  | 2019 |  | 2020
Accounts receivable | ​ | $ | 253,504 | ​ | $ | 274,364
Less allowance for doubtful accounts | ​ |  | (15,064) | ​ |  | (16,859)
Total | ​ | $ | 238,440 | ​ | $ | 257,505
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | March 31,
Inventories | ​ | 2019 | ​ | 2020
Raw materials | ​ | $ | 143,697 | ​ | $ | 133,720
Work-in-process | ​ |  | 67,897 | ​ |  | 59,070
Finished goods | ​ |  | 62,117 | ​ |  | 48,527
Total | ​ | $ | 273,711 | ​ | $ | 241,317

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | March 31,
Property and equipment, net |  | 2019 |  | 2020
Land | ​ | $ | 16,564 | ​ | $ | 16,513
Buildings, civil works and improvements | ​ | ​ | 55,391 | ​ | ​ | 55,574
Leasehold improvements | ​ | ​ | 8,311 | ​ |  | 8,628
Equipment and tooling | ​ | ​ | 128,428 | ​ | ​ | 128,638
Furniture and fixtures | ​ | ​ | 3,190 | ​ | ​ | 3,154
Computer equipment | ​ | ​ | 18,733 | ​ | ​ | 18,525
Computer software | ​ | ​ | 20,146 | ​ | ​ | 19,953
Computer software implementation in process | ​ | ​ | 8,563 | ​ | ​ | 11,019
Construction in process | ​ |  | 5,760 | ​ |  | 6,307
Total | ​ | ​ | 265,086 | ​ |  | 268,311
Less accumulated depreciation and amortization | ​ | ​ | (137,701) | ​ |  | (139,793)
Property and equipment, net | ​ | $ | 127,385 | ​ | $ | 128,518

​

16

Table of Contents

Depreciation and amortization expense for property and equipment was $5.1 million and $5.4 million for the three months ended March 31, 2019 and 2020, respectively, and $15.4 million and $15.9 million for the nine months ended March 31, 2019 and 2020, respectively.

​

4. Goodwill and Intangible Assets

​

The changes in the carrying value of goodwill by segment for the nine-month period ended March 31, 2020 are as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Optoelectronics | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | and | ​ | ​ | ​
​ |  | Security |  | Healthcare |  | Manufacturing |  | ​ | ​
​ | ​ | Division | ​ | Division | ​ | Division | ​ | Consolidated
Balance as of June 30, 2019 | ​ | $ | 200,079 | ​ | $ | 40,064 | ​ | $ | 66,965 | ​ | $ | 307,108
Goodwill acquired or adjusted during the period | ​ |  | 2,213 | ​ | ​ | — | ​ | ​ | 1,033 | ​ | ​ | 3,246
Foreign currency translation adjustment | ​ |  | (517) | ​ |  | (55) | ​ |  | (1,143) | ​ |  | (1,715)
Balance as of March 31, 2020 | ​ | $ | 201,775 | ​ | $ | 40,009 | ​ | $ | 66,855 | ​ | $ | 308,639

​

Intangible assets consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | June 30, 2019 | ​ | March 31, 2020
​ | ​ | Weighted | ​ | Gross | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Gross | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Average | ​ | Carrying | ​ | Accumulated | ​ | Intangibles | ​ | Carrying | ​ | Accumulated | ​ | Intangibles
​ |  | Lives |  | Value |  | Amortization |  | Net |  | Value |  | Amortization |  | Net
Amortizable assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Software development costs | ​ | 8 years | ​ | $ | 29,393 | ​ | $ | (12,747) | ​ | $ | 16,646 | ​ | $ | 37,129 | ​ | $ | (15,553) | ​ | $ | 21,576
Patents | ​ | 19 years | ​ |  | 8,688 | ​ |  | (1,927) | ​ |  | 6,761 | ​ |  | 9,681 | ​ | ​ | (2,481) | ​ | ​ | 7,200
Developed technology | ​ | 10 years | ​ |  | 53,460 | ​ |  | (14,050) | ​ |  | 39,410 | ​ |  | 54,804 | ​ | ​ | (18,135) | ​ | ​ | 36,669
Customer relationships/backlog | ​ | 7 years | ​ |  | 63,101 | ​ |  | (22,132) | ​ |  | 40,969 | ​ |  | 63,244 | ​ | ​ | (28,144) | ​ | ​ | 35,100
Total amortizable assets | ​ | ​ | ​ |  | 154,642 | ​ |  | (50,856) | ​ |  | 103,786 | ​ |  | 164,858 | ​ | ​ | (64,313) | ​ | ​ | 100,545
Non-amortizable assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
IPR&D | ​ | ​ | ​ | ​ | 2,290 | ​ | ​ | — | ​ | ​ | 2,290 | ​ | ​ | 2,200 | ​ | ​ | — | ​ | ​ | 2,200
Trademarks | ​ | ​ | ​ |  | 26,878 | ​ |  | — | ​ |  | 26,878 | ​ |  | 26,726 | ​ | ​ | — | ​ | ​ | 26,726
Total intangible assets | ​ | ​ | ​ | $ | 183,810 | ​ | $ | (50,856) | ​ | $ | 132,954 | ​ | $ | 193,784 | ​ | $ | (64,313) | ​ | $ | 129,471

​

Amortization expense related to intangible assets was $5.4 million and $4.9 million for the three-month periods ended March 31, 2019 and 2020, respectively. For the nine months ended March 31, 2019 and 2020, amortization expense related to intangible assets was $16.3 million and $14.3 million, respectively.

​

At March 31, 2020, the estimated future amortization expense for intangible assets was as follows (in thousands):

​

​ | ​ | ​ | ​
2020 (remaining 3 months) |  | $ | 4,639
2021 | ​ |  | 18,294
2022 | ​ |  | 15,581
2023 | ​ |  | 14,286
2024 | ​ |  | 13,543
Thereafter, including assets that have not yet begun to be amortized | ​ |  | 34,202
Total | ​ | $ | 100,545

​

Software development costs for software products incurred before establishing technological feasibility are charged to operations. Software development costs incurred after establishing technological feasibility are capitalized on a product by product basis until the product is available for general release to customers at which time amortization begins. Annual amortization, charged to cost of goods sold, is the amount computed using the ratio that current revenues for a product bear to the total current and anticipated future revenues for that product. In the event that future revenues are not estimable, such costs are amortized on a straight-line basis over the remaining estimated economic life of the product. Amortizable assets that have not yet begun to be amortized are included in Thereafter in the table above. For the three months ended March 31, 2019 and 2020, we capitalized software development costs in the amounts of $0.8 million and $4.5 million, respectively. For the nine months ended March 31, 2019 and 2020, we capitalized software development costs in the amounts of $1.8 million and $7.7 million, respectively.

​

17

Table of Contents

5. Impairment, Restructuring and Other Charges

​

We endeavor to align our global capacity and infrastructure with demand by our customers as well as fully integrate acquisitions and thereby improve operational efficiency.

​

During the three and nine months ended March 31, 2020, we abandoned a non-core product line in our Healthcare division which resulted in the write-off of assets, including intangible and fixed assets, totaling $3.3 million as we determined that these assets had no value and were permanently impaired. In addition, we continued to recover certain legal costs related to class action litigation and government investigations through insurance reimbursement. We also incurred additional legal fees related to these matters as well as restructuring charges by the divisions as noted in the tables below. This resulted in a net expense of $4.5 million and $1.5 million during the three and nine months ended March 31, 2020, respectively.

​

During the three and nine months ended March 31, 2019, we recovered certain legal costs related to class action litigation and government investigations through insurance reimbursements. We also incurred additional legal fees related to these matters as well as restructuring charges by the divisions as noted in the tables below. This resulted in a net (benefit) expense of $(1.8) million and $1.2 million for the three and nine months ended March 31, 2019, respectively.

​

The following tables summarize impairment, restructuring and other charges (benefit), net for the periods set forth below (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2019
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Optoelectronics and | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Healthcare | ​ | Manufacturing | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Security Division |  | Division |  | Division |  | Corporate |  | Total
Legal costs (recoveries), net | ​ | $ | — | ​ | $ | — | ​ | $ | — | ​ | $ | (1,777) | ​ | $ | (1,777)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2020
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Optoelectronics and | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Healthcare | ​ | Manufacturing | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Security Division |  | Division |  | Division |  | Corporate |  | Total
Impairment charges | ​ | $ | — | ​ | $ | 3,258 | ​ | $ | — | ​ | $ | — | ​ | $ | 3,258
Acquisition-related costs | ​ | ​ | 107 | ​ | ​ | — | ​ | ​ | 41 | ​ | ​ | 155 | ​ | ​ | 303
Employee termination costs | ​ | ​ | 328 | ​ | ​ | 466 | ​ | ​ | 259 | ​ | ​ | 50 | ​ | ​ | 1,103
Facility closures/consolidation | ​ | ​ | 30 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 30
Legal costs (recoveries), net | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (146) | ​ |  | (146)
Total expensed | ​ | $ | 465 | ​ | $ | 3,724 | ​ | $ | 300 | ​ | $ | 59 | ​ | $ | 4,548

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31, 2019
​ |  | ​ | ​ |  | ​ | ​ |  | Optoelectronics and |  | ​ | ​ |  | ​ | ​
​ | ​ | ​ | ​ | ​ | Healthcare | ​ | Manufacturing | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Security Division | ​ | Division | ​ | Division | ​ | Corporate | ​ | Total
Acquisition-related costs | ​ | $ | — | ​ | $ | — | ​ | $ | 287 | ​ | $ | — | ​ | $ | 287
Employee termination costs | ​ |  | — | ​ |  | 1,442 | ​ |  | 133 | ​ |  | — | ​ |  | 1,575
Facility closures/consolidation | ​ |  | — | ​ |  | 2,084 | ​ |  | — | ​ |  | — | ​ |  | 2,084
Legal costs (recoveries), net | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (2,792) | ​ |  | (2,792)
Total expensed | ​ | $ | — | ​ | $ | 3,526 | ​ | $ | 420 | ​ | $ | (2,792) | ​ | $ | 1,154

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31, 2020
​ |  | ​ | ​ |  | ​ | ​ |  | Optoelectronics and |  | ​ | ​ |  | ​ | ​
​ | ​ | ​ | ​ | ​ | Healthcare | ​ | Manufacturing | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Security Division | ​ | Division | ​ | Division | ​ | Corporate | ​ | Total
Impairment charges | ​ | $ | — | ​ | $ | 3,258 | ​ | $ | — | ​ | $ | — | ​ | $ | 3,258
Acquisition-related costs | ​ | ​ | 107 | ​ | ​ | — | ​ | ​ | 41 | ​ | ​ | 155 | ​ | ​ | 303
Employee termination costs | ​ |  | 734 | ​ |  | 466 | ​ |  | 277 | ​ |  | 119 | ​ |  | 1,596
Facility closures/consolidation | ​ |  | 30 | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | 30
Legal costs (recoveries), net | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (3,667) | ​ |  | (3,667)
Total expensed | ​ | $ | 871 | ​ | $ | 3,724 | ​ | $ | 318 | ​ | $ | (3,393) | ​ | $ | 1,520

​

18

Table of Contents

The changes in the accrued liability for restructuring and other charges for the nine-month period ended March 31, 2020 were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Facility | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Employee | ​ | Closure/ | ​ | ​ | ​ | ​ | ​
​ | ​ | Acquisition- | ​ | Termination | ​ | Consolidation | ​ | Legal Costs and | ​ | ​ | ​
​ |  | related Costs |  | Costs |  | Cost |  | Settlements |  | Total
Balance as of June 30, 2019 | ​ | $ | — | ​ | $ | 432 | ​ | $ | — | ​ | $ | 6,331 | ​ | $ | 6,763
Restructuring and other charges (benefit), net | ​ | ​ | 303 | ​ |  | 1,596 | ​ | ​ | 30 | ​ | ​ | (3,667) | ​ |  | (1,738)
(Payments), adjustments and reimbursements, net | ​ | ​ | (303) | ​ | ​ | (2,022) | ​ | ​ | (30) | ​ | ​ | 1,204 | ​ |  | (1,151)
Balance as of March 31, 2020 | ​ | $ | — | ​ | $ | 6 | ​ | $ | — | ​ | $ | 3,868 | ​ | $ | 3,874

​

​

6. Borrowings

​

Revolving Credit Facility

​

Under our revolving credit facility, the aggregate committed amount available to us is $535 million. The credit facility matures in April 2024. The credit facility includes a $300 million sub-limit for letters of credit. Under certain circumstances, we have the ability to increase the facility by the greater of $250 million or such amount as would not cause our secured leverage ratio to exceed a specified level. Borrowings under this facility bear interest at LIBOR plus a margin of 1.0% as of March 31, 2020 (which margin can range from 1.0% to 1.75% based on our consolidated net leverage ratio as defined in the credit facility). The LIBOR index is expected to be discontinued by the end of calendar year 2021. The terms of our revolving credit facility allow for a replacement rate if the LIBOR index is discontinued. Letters of credit reduce the amount available to borrow by their face value amounts. The unused portion of the facility bears a commitment fee of 0.10% as of March 31, 2020 (which fee can range from 0.10% to 0.25% based on our consolidated net leverage ratio as defined in the credit facility). Our borrowings under the credit agreement are guaranteed by certain of our U.S.-based subsidiaries and are secured by substantially all of our assets and substantially all the assets of certain of our subsidiaries. The agreement contains various representations and warranties, affirmative, negative and financial covenants and conditions of default. As of March 31, 2020, there was $95.0 million of borrowings outstanding under the revolving credit facility and $48.1 million outstanding under the letters of credit sub facility. The amount available to borrow under the credit facility as of March 31, 2020 was $391.9 million. Loan amounts under the revolving credit facility may be borrowed, repaid and re-borrowed during the term. Although the principal amount of each revolving loan is due and payable in full on the maturity date, we have the right to repay each revolving loan in whole or in part from time to time without penalty. It is our practice to routinely borrow and repay several times per year under this revolving facility. Therefore, borrowings under the credit facility are included in current liabilities. As of March 31, 2020, we were in compliance with all covenants under this credit facility.

​

1.25% Convertible Senior Notes Due 2022

​

In February 2017, we issued $287.5 million of the Notes in a private offering. The Notes are governed by an indenture dated February 22, 2017. The maturity for the payment of principal is September 1, 2022. The Notes bear interest at the rate of 1.25% and are payable in cash semiannually in arrears on each March 1 and September 1. The Notes are senior unsecured obligations and rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to any of our unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries, as well as any of our existing and future indebtedness that may be guaranteed by our subsidiaries to the extent of such guarantees (including the guarantees of certain of our subsidiaries under our existing revolving credit facility).

​

The Notes are convertible prior to March 1, 2022 only upon specified events and during specified periods and are, thereafter convertible, at any time, in each case at an initial conversion rate of 9.3056 per $1,000 principal amount of the Notes, which is equal to an initial conversion price of approximately $107.46 per share or a 38.5% premium to our stock price at the time of the issuance. The conversion rate is subject to adjustment upon certain events. Upon conversion, the Notes may be settled, at our election, in shares of our common stock, cash or a combination of cash and shares of common stock. We have initially elected a combination settlement method to satisfy the conversion obligation, which allows us to settle the principal amount of the Notes in cash and to settle the excess conversion value, if any, in shares of common stock, as well as cash in lieu of fractional shares.

​

19

Table of Contents

We may redeem the Notes if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any period of 30 consecutive trading days. If we undergo a fundamental change, as defined in the indenture for the Notes, subject to certain conditions, holders of the Notes may require us to repurchase all or part of the Notes for cash at a price equal to 100% of the principal amount of the Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The occurrence of a fundamental change will also result in the Notes becoming immediately convertible. Since the last reported sales price of our Common Stock did not exceed 130% of the conversion price for at least 20 trading days within any applicable period of 30 consecutive trading days during the three months ended March 31, 2020, the Notes are not yet convertible.

​

Pursuant to ASC 470-20, we allocated the $287.5 million gross proceeds of the Notes between liability and equity components. The initial $242.4 million liability component was determined based on the fair value of similar debt instruments excluding the conversion feature for similar terms and priced on the same day the Notes were issued. The initial $45.1 million equity component represents the debt discount and was calculated as the difference between the fair value of the debt and the gross proceeds of the Notes. Issuance costs of $7.7 million were allocated between debt ($6.5 million) and equity ($1.2 million) components with the portion allocated to the debt presented as an offset against long term debt in the consolidated balance sheet and being amortized as interest expense over the life of the Notes using the effective interest method. The total interest expense recognized for the three and nine months ended March 31, 2020 related to the Notes was $3.3 million and $9.7 million, respectively, which consisted of $0.9 million and $2.7 million of contractual interest expense, $2.1 million and $6.1 million of debt discount amortization and $0.3 million and $0.9 million of amortization of debt issuance costs. The total interest expense recognized for the three months and nine months ended March 31, 2019 was $3.2 million and $9.4 million, respectively, which consisted of $0.9 million and $2.7 million of contractual interest expense, $2.0 million and $5.8 million of debt discount amortization and $0.3 million and $0.9 million of amortization of debt issuance costs. As of June 30, 2019 and March 31, 2020, the unamortized debt discount was $27.3 million and $21.2 million, respectively, which is being amortized over the remaining contractual term to maturity of the Notes using an effective interest rate of 4.50%. The unamortized debt issuance cost of $3.7 million and $2.8 million as of June 30, 2019 and March 31, 2020, respectively, is amortized on a straight-line basis, which approximates the effective interest method, over the life of the Notes.

​

Other Borrowings

​

Several of our foreign subsidiaries maintain bank lines-of-credit, denominated in local currencies and U.S. dollars, primarily for the issuance of letters-of-credit. As of March 31, 2020, $41.6 million was outstanding under these letter-of-credit facilities. As of March 31, 2020, the total amount available under these credit facilities was $24.2 million.

​

Long-term debt consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | March 31,
​ |  | 2019 |  | 2020
1.25% convertible notes due 2022: | ​ | ​ | ​ | ​ | ​ | ​
Principal amount | ​ | $ | 287,500 | ​ | $ | 287,500
Unamortized discount | ​ | ​ | (27,283) | ​ |  | (21,165)
Unamortized debt issuance costs | ​ |  | (3,722) | ​ |  | (2,841)
​ | ​ |  | 256,495 | ​ |  | 263,494
Other long-term debt | ​ | ​ | 2,061 | ​ | ​ | 2,186
​ | ​ | ​ | 258,556 | ​ | ​ | 265,680
Less current portion of long-term debt | ​ | ​ | (804) | ​ | ​ | (903)
Long-term portion of debt | ​ | $ | 257,752 | ​ | $ | 264,777

​

​

7. Stockholders’ Equity

​

Stock-based Compensation

​

As of March 31, 2020, we maintained the Amended and Restated 2012 Incentive Award Plan (the "2012 Plan ") and the Amended and Restated 2006 Equity Participation Plan ("2006 Plan") as stock-based employee compensation plans. No further grants may be made under the 2006 Plan. The 2012 Plan and the 2006 Plan are collectively referred to as the "OSI Plans."

​

20

Table of Contents

We recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | Nine Months Ended March 31,
​ |  | 2019 |  | 2020 |  | 2019 |  | 2020
Cost of goods sold | ​ | $ | 182 | ​ | $ | 189 | ​ | $ | 539 | ​ | $ | 517
Selling, general and administrative | ​ | ​ | 5,543 | ​ | ​ | 5,520 | ​ |  | 18,487 | ​ |  | 17,153
Research and development | ​ | ​ | 163 | ​ | ​ | 129 | ​ |  | 488 | ​ |  | 427
Stock-based compensation expense | ​ | $ | 5,888 | ​ | $ | 5,838 | ​ | $ | 19,514 | ​ | $ | 18,097

​

As of March 31, 2020, total unrecognized compensation cost related to share-based compensation grants under the OSI Plans were estimated at $0.5 million for stock options and $18.9 million for RSUs. We expect to recognize these costs over a weighted average period of 2.0 years with respect to the stock options and 1.9 years for grants of RSUs.

​

The following summarizes stock option activity during the nine months ended March 31, 2020:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted Average | ​ | Weighted-Average | ​ | Aggregate
​ | ​ | Number of | ​ | Exercise | ​ | Remaining Contractual | ​ | Intrinsic Value
​ |  | Options |  | Price |  | Term |  | (in thousands)
Outstanding at June 30, 2019 |  | 515,884 | ​ | $ | 33.74 | ​ | ​ | ​ | ​ | ​
Granted |  | 13,263 | ​ | ​ | 101.31 | ​ | ​ | ​ | ​ | ​
Exercised |  | (201,003) | ​ | ​ | 20.45 | ​ | ​ | ​ | ​ | ​
Expired or forfeited |  | (1,092) | ​ | ​ | 85.37 | ​ | ​ | ​ | ​ | ​
Outstanding at March 31, 2020 |  | 327,052 | ​ | ​ | 44.47 |  | 2.7 years | ​ | $ | 8,867
Exercisable at March 31, 2020 |  | 295,525 | ​ | ​ | 39.85 |  | 2.0 years | ​ | ​ | 8,867

​

The following summarizes RSU award activity during the nine months ended March 31, 2020:

​

​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted-
​ | ​ | ​ | ​ | Average
​ |  | Shares |  | Fair Value
Nonvested at June 30, 2019 |  | 521,140 | ​ | $ | 73.97
Granted |  | 300,998 | ​ | ​ | 88.26
Vested |  | (388,756) | ​ | ​ | 68.60
Forfeited |  | (13,907) | ​ | ​ | 83.24
Nonvested at March 31, 2020 |  | 419,475 | ​ | ​ | 88.89

​

As of March 31, 2020, there were approximately 1.0 million shares available for grant under the 2012 Plan. Under the terms of the 2012 Plan, RSUs and restricted stock granted from the pool of shares available for grant reduce the pool by 1.87 shares for each award granted. RSUs and restricted stock forfeited and returned to the pool of shares available for grant increase the pool by 1.87 shares for each award forfeited.

​

We granted 97,514 and 81,621 performance-based RSUs during the nine months ended March 31, 2019 and 2020, respectively. These performance based RSU awards are contingent on the achievement of certain performance metrics. The payout related to these awards can range from zero to 280% of the original number of shares or units awarded.

​

Stock Repurchase Program

​

In March 2018, the Board of Directors authorized a stock repurchase program of up to 1,000,000 shares, which was completed during the three months ended March 31, 2020. In April 2020, the Board of Directors authorized a new share repurchase program of up to 1,000,000 shares. This program does not expire unless our Board of Directors acts to terminate the program. The timing and actual numbers of shares purchased depends on a variety of factors, including stock price, general business and market conditions and other investment opportunities. Repurchases may be made from time to time under the program through open-market purchases or privately-negotiated transactions at our discretion. Upon repurchase, the shares are restored to the status of authorized but unissued shares and we record them as a reduction in the number of shares of Common Stock issued and outstanding in our consolidated financial statements.

​

During the nine months ended March 31, 2020, we repurchased 562,707 shares of our common stock.

21

Table of Contents

​

Dividends

​

We have not paid any cash dividends since the consummation of our initial public offering in 1997 and we do not currently intend to pay any cash dividends in the foreseeable future. Our Board of Directors will determine the payment of future cash dividends, if any. Certain of our current bank credit facilities restrict the payment of cash dividends and future borrowings may contain similar restrictions.

​

8. Retirement Benefit Plans

​

We sponsor various retirement benefit plans including qualified and nonqualified defined benefit pension plans for our employees. The components of net periodic pension expense are as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | Nine Months Ended March 31,
​ |  | 2019 |  | 2020 |  | 2019 |  | 2020
Service cost | ​ | $ | 98 | ​ | $ | 100 | ​ | $ | 295 | ​ | $ | 300
Interest cost | ​ | ​ | 8 | ​ | ​ | 8 | ​ | ​ | 25 | ​ | ​ | 24
Amortization of prior service cost | ​ | ​ | 14 | ​ | ​ | 13 | ​ |  | 42 | ​ |  | 39
Net periodic pension expense | ​ | $ | 120 | ​ | $ | 121 | ​ | $ | 362 | ​ | $ | 363

​

For the three months ended March 31, 2019, we made no contributions to these defined benefit plans. For the nine months ended March 31, 2019, we made contributions of $1.0 million to these defined benefit plans. For the three and nine months ended March 31, 2020, we made no contributions to these defined benefit plans.

​

We also maintain various defined contribution plans. For the three months ended March 31, 2019 and 2020, we made contributions of $1.6 million and $1.8 million, respectively, to these defined contribution plans. For the nine months ended March 31, 2019 and 2020, we made contributions of $4.7 million and $5.0 million, respectively, to these defined contribution plans.

​

9. Commitments and Contingencies

​

COVID-19

​

Our operations expose us to risks associated with pandemics, epidemics or other public health emergencies, such as the recent outbreak of coronavirus disease 2019 (COVID-19). The rapid spread of COVID-19 and the continuously evolving responses to combat it have had an increasingly negative impact on the global economy. Because of the rapidly changing business environment, unprecedented market volatility and high degree of uncertainty resulting from COVID-19, the extent to which COVID-19 will adversely impact our business is highly uncertain and unpredictable. While COVID-19 has negatively impacted, and is expected to continue to negatively impact, our results of operations, cash flows and financial position, the current level of uncertainty over the economic and operational impacts of COVID-19 means the related financial impact from a prolonged pandemic cannot be reasonably estimated at this time. We are regularly monitoring the potential effects of COVID-19 on our results of operations, cash flows and financial position.

​

Acquisition-Related Contingent Obligations

​

Under the terms and conditions of the purchase agreements associated with certain acquisitions, we may be obligated to make additional payments based on the achievement of certain sales or profitability milestones through the acquired operations. For agreements that contain contingent consideration caps, the remaining maximum amount of such potential future payments is $23.7 million as of March 31, 2020.

​

We account for such contingent payments for acquisitions which occurred through the end of fiscal year 2009 as additions to the purchase price of the acquired business. We made $0.1 million and $1.3 million of such payments during the three and nine months ended March 31, 2019, respectively, and $0.2 million and $1.5 million of such payments during the three and nine months ended March 31, 2020, respectively.

​

22

Table of Contents

For acquisitions completed after fiscal 2009, pursuant to Financial Accounting Standard 141R, which was codified into ASC 805, the estimated fair value of these obligations is recorded as a liability at the time of the acquisition with subsequent revisions recorded in Selling, general and administrative expense in the consolidated financial statements. The estimated fair value measurements of contingent earn-out obligations are primarily based on unobservable inputs, which may include projected revenues, gross margins, operating income, and the estimated probability of achieving the earn-outs.

​

These projections and probabilities are used to estimate future contingent earnout payments, which are discounted back to present value to compute contingent earnout liabilities. The following table provides a roll-forward from June 30, 2019 to March 31, 2020 of the contingent consideration liability, which is included in other accrued expenses and current liabilities, and other long-term liabilities in our consolidated balance sheets (in thousands):

​

​ | ​ | ​ | ​
Beginning fair value, June 30, 2019 |  | $ | 16,577
Addition of contingent earnout obligations | ​ | ​ | 1,560
Foreign currency translation adjustment | ​ | ​ | (183)
Changes in fair value for contingent earnout obligations |  | ​ | (946)
Payments on contingent earnout obligations |  | ​ | (3,802)
Ending fair value, March 31, 2020 | ​ | $ | 13,206

​

Environmental Contingencies

​

We are subject to various environmental laws. Our practice is to conduct appropriate environmental investigations at our manufacturing facilities in North America, Asia-Pacific, and Europe, and, to the extent practicable, on all new properties in order to identify, as of the date of such investigation, potential areas of environmental concern related to past and present activities or from nearby operations. In certain cases, we have conducted further environmental assessments consisting of soil and groundwater testing and other investigations deemed appropriate by independent environmental consultants.

​

We continue to investigate contamination of the soil and groundwater beneath the Hawthorne, California facility that resulted from unspecified on-and off-site releases occurring prior to our occupancy. We believe the releases are of a historical nature and not uncommon to the region in general. We continue to take voluntary actions, in cooperation with the local governing agency, to fully investigate the site in order to develop appropriate remedial actions.

​

We have not accrued for loss contingencies relating to the Hawthorne facility or any other environmental matters because we believe that, although unfavorable outcomes may be possible, they are not considered by our management to be probable and reasonably estimable. If one or more of these environmental matters are resolved in a manner adverse to us, the impact on our business, financial condition, results of operations and cash flow could be material.

​

Indemnifications and Certain Employment-Related Contingencies

​

In the normal course of business, we have agreed to indemnify certain parties with respect to certain matters. We have agreed to hold certain parties harmless against losses arising from a breach of representations, warranties or covenants, or intellectual property infringement or other claims made by third parties. These agreements may limit the time within which an indemnification claim can be made and the amount of the claim. In addition, we have entered into indemnification agreements with our directors and certain of our officers. It is not possible to determine the maximum potential amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. We have not recorded any liability for costs related to contingent indemnification obligations as of March 31, 2020.

​

On December 31, 2017, we and Deepak Chopra, our Chief Executive Officer, entered into an amendment to Mr. Chopra's employment agreement that, among other things, provides for a $13.5 million bonus payment to Mr. Chopra on or within 45 days of January 1, 2024 contingent upon Mr. Chopra's continued employment with us through that date, subject to accelerated payout terms in the event of Mr. Chopra's death or disability. The bonus is recorded in the financial statements over the remaining term of the employment agreement and is included in other long-term liabilities.

​

23

Table of Contents

Product Warranties

​

We offer our customers warranties on many of the products that we sell. These warranties typically provide for repairs and maintenance of the products if problems arise during a specified time period after original shipment. Concurrent with the sale of products, we record a provision for estimated warranty expenses with a corresponding increase in cost of goods sold. We periodically adjust this provision based on historical experience and anticipated expenses. We charge actual expenses of repairs under warranty, including parts and labor, to this provision when incurred. The current obligation for warranty provision is included in other accrued expenses and current liabilities and the noncurrent portion is included in other long-term liabilities in the consolidated balance sheets.

​

The following table presents changes in warranty provisions (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31,
​ |  | 2019 |  | 2020
Balance at beginning of period | ​ | $ | 21,819 | ​ | $ | 21,724
Additions and adjustments | ​ | ​ | 7,135 | ​ | ​ | 6,105
Reductions for warranty repair costs | ​ |  | (6,545) | ​ |  | (6,557)
Balance at end of period | ​ | $ | 22,409 | ​ | $ | 21,272

​

Legal Proceedings

​

In December 2017, a short seller released a report regarding our compliance with the FCPA. Following that report, we and certain of our executive officers have been named as defendants in several lawsuits in the United States District Court for the Central District of California (the "District Court") that were filed in December 2017 and February 2018. Each of the complaints closely tracks the allegations set forth in the short seller's report. All of the actions, which were consolidated by the District Court in March 2018 in an action captioned Arkansas Teacher Retirement System et al. v. OSI Systems, Inc. et al., No. 17 cv 08841, allege violations of Sections 10(b) and 20(a) of the Exchange Act, relating to certain of our public statements and filings with the SEC, and seek damages and other relief based upon the allegations in the complaints. In April 2018 and March 2019, two shareholder derivative complaints were filed purportedly on behalf of the Company against certain members of our Board of Directors (as individual defendants), a former member of our Board of Directors, and a member of management. The derivative actions, which were consolidated by the District Court in November 2019 in an action captioned Kocen and Riley v. Chopra, et al. No. 18 CV 03371, allege, among other things, breach of fiduciary duties relating to the allegations contained in the above-mentioned short seller report and seek damages, restitution, injunctive relief, attorneys' and experts' fees, costs, expenses, and other unspecified relief. We believe that the actions are without merit and intend to defend them vigorously, and we expect to incur costs associated with defending against these actions. At this early stage of the litigations, the ultimate outcomes are uncertain and we cannot reasonably predict the timing or outcomes, or estimate the amount of loss, if any, or their effect, if any, on our financial statements.

​

The SEC and the U.S. Department of Justice (“DOJ”) are conducting an investigation of trading in our securities and have each subpoenaed information regarding trading by executives, directors, and employees, as well as our operations and disclosures in and around the time of certain trades. With respect to these trading related matters, in fiscal year 2018, we took action with respect to a senior level employee. At this time, we are unable to predict what, if any, action may be taken by the DOJ or SEC as a result of these trading related investigations, or any penalties or remedial measures these agencies may seek. We place a high priority on compliance with our anticorruption and securities trading policies and are cooperating with each of the government investigations.

​

We are involved in various other claims and legal proceedings arising in the ordinary course of business. In our opinion after consultation with legal counsel, the ultimate disposition of such proceedings is not likely to have a material adverse effect on our business, financial condition, results of operations or cash flows. We have not accrued for loss contingencies relating to any such matters because we believe that, although unfavorable outcomes in the proceedings are possible, they are not considered by management to be probable and reasonably estimable. If one or more of these matters are resolved in a manner adverse to our company, the impact on our business, financial condition, results of operations and cash flows could be material.

​

10. Income Taxes

​

The determination of the annual effective tax rate is based upon a number of significant estimates and judgments, including the estimated annual pretax income in each tax jurisdiction in which we operate, and the development of tax planning strategies during the year. In addition, as a global commercial enterprise, our tax expense can be impacted by changes in tax rates or laws, the finalization of tax audits and reviews, and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions.

​

24

Table of Contents

During the three and nine months ended March 31, 2020, we recognized discrete tax benefits of $5.1 million and $12.0 million, respectively, resulting in an effective tax rate of -3.4% and 8.7%, respectively. This included discrete tax benefits primarily related to equity-based compensation under ASU 2016-09 and return to provision true-up adjustments. During the three and nine months ended March 31, 2019, we recognized a tax benefit for equity-based compensation of $0.7 million and $2.6 million, respectively, under ASU 2016-09 resulting in an effective tax rate of 26.0% and 24.2%, respectively. Excluding the impact of the discrete tax items noted above, our effective tax rate for the three and nine months ended March 31, 2020 was 23.7% and 26.7%, respectively, as compared to 28.6% and 28.4% in the prior-year three month and nine month periods, respectively.

​

11. Segment Information

​

We have determined that we operate in three identifiable industry segments: (a) security and inspection systems (Security division), (b) medical monitoring and diagnostic cardiology systems (Healthcare division) and (c) optoelectronic devices and manufacturing (Optoelectronics and Manufacturing division). We also have a corporate segment (Corporate) that includes executive compensation and certain other general and administrative expenses; expenses related to stock issuances and legal, audit and other professional service fees not allocated to industry segments. Both the Security and Healthcare divisions comprise primarily end-product businesses whereas the Optoelectronics and Manufacturing division primarily supplies components and subsystems to external OEM customers, as well as to the Security and Healthcare divisions. Sales between divisions are at transfer prices that approximate market values. All other accounting policies of the segments are the same as described in Note 1, Summary of Significant Accounting Policies of the Form 10-K for the fiscal year ended June 30, 2019.

​

The following tables set forth the results of operations and identifiable assets by industry segment (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, | ​ | Nine Months Ended March 31,
​ |  | 2019 |  | 2020 |  | 2019 |  | 2020
Revenues (1) —by Segment: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Security division | ​ | $ | 193,486 | ​ | $ | 187,076 | ​ | $ | 552,130 | ​ | $ | 578,477
Healthcare division | ​ | ​ | 48,865 | ​ | ​ | 45,662 | ​ |  | 138,697 | ​ |  | 127,862
Optoelectronics and Manufacturing division, including intersegment revenues | ​ | ​ | 70,927 | ​ | ​ | 70,240 | ​ |  | 213,900 | ​ |  | 216,684
Intersegment revenues elimination | ​ | ​ | (8,994) | ​ | ​ | (10,095) | ​ |  | (30,989) | ​ |  | (33,946)
Total | ​ | $ | 304,284 | ​ | $ | 292,883 | ​ | $ | 873,738 | ​ | $ | 889,077
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income (loss) from operations —by Segment: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Security division | ​ | $ | 24,943 | ​ | $ | 24,525 | ​ | $ | 74,056 | ​ | $ | 73,405
Healthcare division | ​ | ​ | 5,418 | ​ | ​ | 1,682 | ​ |  | 5,752 | ​ |  | 5,793
Optoelectronics and Manufacturing division | ​ | ​ | 7,320 | ​ | ​ | 7,309 | ​ |  | 22,212 | ​ |  | 25,096
Corporate | ​ | ​ | (5,354) | ​ | ​ | (10,161) | ​ |  | (21,265) | ​ |  | (23,578)
Eliminations | ​ | ​ | (207) | ​ | ​ | 270 | ​ |  | (671) | ​ |  | 715
Total | ​ | $ | 32,120 | ​ | $ | 23,625 | ​ | $ | 80,084 | ​ | $ | 81,431

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | March 31,
​ |  | 2019 |  | 2020
Assets (2) —by Segment: | ​ | ​ | ​ | ​ | ​ | ​
Security division | ​ | $ | 793,810 | ​ | $ | 784,736
Healthcare division | ​ |  | 157,639 | ​ |  | 199,645
Optoelectronics and Manufacturing division | ​ |  | 237,851 | ​ |  | 241,824
Corporate | ​ |  | 79,498 | ​ |  | 101,419
Eliminations (3) | ​ |  | (3,934) | ​ |  | (41,030)
Total | ​ | $ | 1,264,864 | ​ | $ | 1,286,594

(1)For each of the three and nine month periods ended March 31, 2019 and March 31, 2020, no customer accounted for greater than 10% of total net revenues.
(2)One customer accounted for 16% of accounts receivable, net as of March 31, 2020. No customer accounted for 10% or more of accounts receivable, net as of June 30, 2019.
(3)Eliminations in assets reflect the amount of intercompany profits in inventory and intercompany ROU assets under ASC 842 as of the balance sheet date. Such intercompany profit will be realized when inventory is shipped to the external customers of the Security and Healthcare divisions.

​

​

​

25

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

​

In this report, “OSI”, the “Company”, “we”, “us”, “our” and similar terms refer to OSI Systems, Inc. together with our wholly-owned subsidiaries.

​

This management’s discussion and analysis of financial condition as of March 31, 2020 and results of operations for the three and nine months ended March 31, 2020 should be read in conjunction with management’s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended June 30, 2019 filed with the SEC.

​

Forward-Looking Statements

​

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements relate to current expectations, beliefs, and projections concerning matters that are not historical facts. Words such as “project,” “believe,” “anticipate,” “plan,” “expect,” “intend,” “may,” “should,” “will,” “would,” and similar words and expressions are intended to identify forward-looking statements. The expectations, beliefs, and projections reflected in the forward-looking statements may prove to be inaccurate, and actual results may differ materially from those reflected in such forward-looking statements. Important factors that could cause our actual results to differ materially from those expectations are disclosed in this report, our Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (including Part I, Item 1, “Business,” Part I, Item 1A, “Risk Factors” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”), and other documents filed by us from time to time with the SEC. Such factors, of course, do not include all factors that might affect our business and financial condition. Although we believe that the assumptions upon which our forward-looking statements are based are reasonable, such assumptions could prove to be inaccurate and actual results could differ materially from those expressed in or implied by the forward-looking statements. For example, we could be exposed to a variety of negative consequences as a result of delays related to the award of domestic and international contracts; failure to secure the renewal of key customer contracts; delays in customer programs; delays in revenue recognition related to the timing of customer acceptance; unanticipated impacts of sequestration and other U.S. Government budget control provisions; changes in domestic and foreign government spending, budgetary, procurement and trade policies adverse to our businesses; global economic uncertainty; impacts on our business related to or resulting from the COVID-19 pandemic; unfavorable currency exchange rate fluctuations; effect of changes in tax legislation; market acceptance of our new and existing technologies, products and services; our ability to win new business and convert any orders received to sales within the fiscal year; enforcement actions in respect of any noncompliance with laws and regulations including export control and environmental regulations and the matters that are the subject of some or all of our investigations and compliance reviews, contract and regulatory compliance matters, and actions, which if brought, could result in judgments, settlements, fines, injunctions, debarment or penalties, and other risks and uncertainties, including, but not limited to, those detailed herein and from time to time in our other SEC filings, which could have a material and adverse impact on our business, financial condition and results of operations. All forward-looking statements contained in this report are qualified in their entirety by this statement. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this report may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Investors should not place undue reliance on forward-looking statements as a prediction of actual results. We undertake no obligation other than as may be required under securities laws to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

​

Executive Summary

​

We are a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications. We sell our products and provide related services in diversified markets, including homeland security, healthcare, defense and aerospace. We have three operating divisions: (a) Security, providing security and inspection systems and turnkey security screening solutions; (b) Healthcare, providing patient monitoring and diagnostic cardiology systems; and (c) Optoelectronics and Manufacturing, providing specialized electronic components for our Security and Healthcare divisions, as well as to third parties for applications in the defense and aerospace markets, among others.

​

26

Table of Contents

Security Division. Through our Security division, we provide security screening products and services internationally, as well as turnkey security screening solutions. These products and services are used to inspect baggage, parcels, cargo, people, vehicles and other objects for weapons, explosives, drugs, radioactive and nuclear materials and other contraband. Revenues from our Security division accounted for 63% and 65% of our total consolidated revenues for the nine months ended March 31, 2019 and 2020, respectively.

​

Healthcare Division. Through our Healthcare division, we design, manufacture, market and service patient monitoring and diagnostic cardiology systems internationally for sale primarily to hospitals and medical centers. Our products monitor patients in critical, emergency and perioperative care areas of the hospital and provide information, through wired and wireless networks, to physicians and nurses who may be at the patient's bedside, in another area of the hospital or even outside the hospital. Revenues from our Healthcare division accounted for 16% and 14% of our total consolidated revenues for the nine months ended March 31, 2019 and 2020, respectively.

​

Optoelectronics and Manufacturing Division. Through our Optoelectronics and Manufacturing division, we design, manufacture and market optoelectronic devices and flex circuits and provide electronics manufacturing services internationally for use in a broad range of applications, including aerospace and defense electronics, security and inspection systems, medical imaging and diagnostics, telecommunications, office automation, computer peripherals, industrial automation, automotive diagnostic systems, and consumer products. We also provide our optoelectronic devices and electronics manufacturing services to OEM customers, and our own Security and Healthcare divisions. Revenues from external customers in our Optoelectronics and Manufacturing division accounted for 21% and 21% of our total consolidated revenues for the nine months ended March 31, 2019 and 2020, respectively.

​

Trends and Uncertainties

​

The following is a discussion of certain trends and uncertainties that we believe have influenced, and may continue to influence our results of operations.

​

Coronavirus Pandemic. The recent novel coronavirus (COVID-19) outbreak has resulted, and is likely to continue to result, in significant economic disruptions and has impacted and is expected to continue to impact our operations and the operations of our suppliers as a result of quarantines, facility closures, and travel and logistics restrictions in connection with the outbreak. While we do not expect these impacts to be long-term, there is uncertainty around the duration and impact of the COVID-19 outbreak. Our Healthcare division has experienced increased near-term term demand for products as a result of COVID-19; however, we expect our other divisions to see adverse changes in the timing of demand for products and services. In our Security division, we expect order activity to be impacted most prominently with respect to our aviation and cargo products. As many of our customers in both our Security and Optoelectronics and Manufacturing divisions are being impacted by the pandemic, we are also receiving requests to delay deliveries of equipment and modify service arrangements, and we are experiencing delays in the timing of orders. In addition, as a result of newly-imposed government regulations, certain of our global manufacturing facilities are not able to operate at optimal utilization. If these business interruptions resulting from COVID-19 were to be prolonged or expanded in scope, our business, financial condition, results of operations, and cash flows could be materially adversely impacted. We will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by federal, state or local authorities or that we determine are in our best interests. For a further discussion of potential risks to our business from the COVID-19 pandemic, see Item 1A. Risk Factors in this quarterly report on Form 10-Q.

​

Global Economic Considerations. In addition to the COVID-19 pandemic, other global macroeconomic factors, coupled with the U.S. political climate, have created uncertainty and impacted demand for certain of our products and services. The current status and potential outcomes of Brexit has contributed to economic uncertainty and could have an adverse impact on our UK business, including our orders and sales operations and personnel in the UK. We do not know how long this uncertainty will continue. Therefore, we expect that there may be a period of delayed or deferred purchasing by our customers. These factors could have a material negative effect on our business, results of operations and financial condition.

​

Our international operations provide a significant portion of our total revenue and expenses. Many of these revenues and expenses are denominated in currencies other than the U.S. dollar, and, as a result, may be significantly affected by changes in foreign exchange rates.

​

27

Table of Contents

Global Trade. In addition to the COVID-19 pandemic, the current domestic and international political environment, including in relation to recent and further potential changes by the U.S. and other countries in policies on global trade and tariffs, have resulted in uncertainty surrounding the future state of the global economy and global trade. This uncertainty is exacerbated by sanctions imposed by the U.S. government against certain businesses and individuals in select countries. Continued or increased uncertainty regarding global trade due to these or other factors may require us to modify our current business practices and could have a material adverse effect on our business, results of operations and financial condition.

​

Healthcare Considerations. As described above, our Healthcare division has experienced some near-term increased demand for its patient monitoring products as a result of the COVID-19 pandemic. However, in prior periods, our results of operations were adversely impacted in by difficulties associated with product launches. These issues may in future periods continue to adversely impact our results of operations. Additionally, there have been numerous efforts advanced by the Trump administration and Congress to repeal and replace or modify the Affordable Care Act, which has created uncertainty in the healthcare industry that has adversely impacted, and may continue to adversely impact, our results of operations.

​

European Union Threat Detection Standards. The EU has implemented regulations for all airports within the EU to have hold baggage screening systems that are compliant with the European Civil Aviation Conference (ECAC) Standard 3 by September 2020. It is unclear whether this deadline will hold or be delayed. Our Security division's real time tomography (RTT) product has passed the ECAC explosive detection system Standard 3 threat detection requirement.

​

Government Policies. Our net income could be affected by changes in U.S. or foreign government policies. For example, the LIBOR index is expected to be discontinued by the end of calendar year 2021. If the LIBOR index is discontinued, the terms of our revolving credit facility allow for a replacement rate to be determined in accordance with the credit agreement. Changes in government policies could impact our financial condition and results of operations.

​

Mexico SAT Contract. Our contract with the Mexican government to provide a turnkey security screening solution at various locations throughout the country is scheduled to expire in May 2020. While we are actively in discussions with the Mexican government for a renewal of the program, we cannot provide any assurance that this program will be continued and, if the program is continued, upon what terms. If the program is discontinued or continued upon modified terms, our results of operations could be materially affected.

​

Results of Operations for the Three Months Ended March 31, 2019 (Q3 2019) Compared to the Three Months Ended March 31, 2020 (Q3 2020) (amounts in millions)

​

Net Revenues

​

The table below and the discussion that follows are based upon the way in which we analyze our business. See Note 11 to the condensed consolidated financial statements for additional information about our business segments.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Q3 |  | % of |  | Q3 |  | % of |  | ​ | ​ |  | ​ |
​ | ​ | 2019 | ​ | Net Revenues | ​ | 2020 | ​ | Net Revenues | ​ | $ Change | ​ | % Change |
Security | ​ | $ | 193.5 |  | 64 | % | $ | 187.1 |  | 64 | % | $ | (6.4) |  | (3) | %
Healthcare | ​ |  | 48.9 |  | 16 | ​ |  | 45.7 |  | 16 | ​ |  | (3.2) |  | (7) | ​
Optoelectronics and Manufacturing | ​ |  | 61.9 |  | 20 | ​ |  | 60.1 |  | 20 | ​ |  | (1.8) |  | (3) | ​
Total net revenues | ​ | $ | 304.3 |  | 100 | % | $ | 292.9 |  | 100 | % | $ | (11.4) |  | (4) | %

​

Revenues for the Security division during the three months ended March 31, 2020 decreased on a year-over-year basis as a result of decreased revenue from cargo and vehicle inspection systems and explosive detection systems, partially offset by an increase in sales of checkpoint equipment. Overall service revenue for the division was comparable to the prior year.

​

Revenues for the Healthcare division during the three months ended March 31, 2020 decreased year-over-year due to lower sales of patient monitoring systems and the exit of a product line.

​

Revenues for the Optoelectronics and Manufacturing division during the three months ended March 31, 2020 decreased year-over-year as a result of reduced revenue in our contract manufacturing business partially offset by the inclusion of revenues from a small business acquired in February 2020.

​

28

Table of Contents

Toward the end of the third quarter of fiscal year 2020, revenues in our Security and Optoelectronics and Manufacturing divisions were adversely impacted as a result of the COVID-19 pandemic.

​

Gross Profit

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Q3 |  | % of |  | Q3 |  | % of |
​ | ​ | 2019 | ​ | Net Revenues | ​ | 2020 | ​ | Net Revenues |
Gross profit | ​ | $ | 111.3 |  | 36.6 | % | $ | 109.1 |  | 37.3 | %

​

Gross profit as a percentage of net revenues during the three months ended March 31, 2020 was higher compared to the prior year due to improved margins in our Security division driven primarily by increased service gross margins as well as increased gross margins in our Healthcare division.

​

Operating Expenses

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Q3 |  | % of |  | Q3 |  | % of |  | ​ | ​ |  | ​ |
​ | ​ | 2019 | ​ | Net Revenues | ​ | 2020 | ​ | Net Revenues | ​ | $ Change | ​ | % Change |
Selling, general and administrative | ​ | $ | 67.3 |  | 22.1 | % | $ | 65.6 |  | 22.4 | % | $ | (1.7) |  | (2.5) | %
Research and development | ​ |  | 13.7 |  | 4.5 | ​ |  | 15.4 |  | 5.2 | ​ |  | 1.7 |  | 12.1 | ​
Impairment, restructuring and other charges (benefit), net | ​ |  | (1.8) |  | (0.6) | ​ |  | 4.5 |  | 1.6 | ​ |  | 6.3 |  | (355.9) | ​
Total operating expenses | ​ | $ | 79.2 |  | 26.0 | % | $ | 85.5 |  | 29.2 | % | $ | 6.3 |  | 7.9 | %

​

Selling, general and administrative. Selling, general and administrative (SG&A) expenses consist primarily of compensation paid to sales, marketing and administrative personnel, professional service fees, sales commissions and marketing expenses. SG&A expense for the three months ended March 31, 2020 was lower than the comparable prior-year period primarily due to reduced sales commission expenses on lower net revenues, as well as lower marketing and travel expenses, partially offset by higher employee compensation expense.

​

Research and development. Research and development (R&D) expenses include research related to new product development and product enhancements. The increase in R&D expenses during the three months ended March 31, 2020 from the same prior-year period reflected increased investment in our Security division primarily to support new product development.

​

Impairment, restructuring and other charges (benefit). Impairment, restructuring and other charges generally consist of charges related to reductions in our workforce, facility consolidation, impairment of assets, costs related to acquisition activity, legal charges and other non-recurring charges. The net expense in the third fiscal quarter of 2020 included $3.3 million from impairment of assets in our Healthcare division for the exit of a product line, $1.1 million of employee termination and facility closure costs and $0.1 million of other net costs. The net benefit in the third fiscal quarter of 2019 was primarily due to a recovery of certain legal costs through insurance reimbursement.

​

Other Income and Expenses

​

Interest and other expense, net. For the three months ended March 31, 2020, interest and other expense, net was $4.7 million as compared to $5.6 million in the comparable prior-year period. This decrease was driven primarily by lower average levels of borrowing under our revolving credit facility as well as lower average interest rates during the three months ended March 31, 2020 compared to the same period in the prior year. Interest expense in the current-year period included $2.2 million of non-cash interest expense primarily related to the Notes (see Note 6 to the condensed consolidated financial statements for further discussion) compared to $2.0 million during the comparable prior-year period.

​

Income taxes. The effective tax rate for a particular period varies depending on a number of factors, including (i) the mix of income earned in various tax jurisdictions, each of which applies a unique range of income tax rates and income tax credits, (ii) changes in previously established valuation allowances for deferred tax assets (changes are based upon our current analysis of the likelihood that these deferred tax assets will be realized), (iii) the level of non-deductible expenses, (iv) certain tax elections (v) tax holidays granted to certain of our international subsidiaries and (vi) discrete tax items. For the three months ended March 31, 2020, we recognized a benefit for income taxes of $(0.6) million compared to a provision for income taxes of $6.9 million for the comparable prior-year period. The effective tax rate for the three months ended March 31, 2019 and 2020 was 26.0% and (3.4)%, respectively. During the three months ended March 31, 2019, we recognized a discrete tax benefit of $0.7 million primarily for equity-based compensation under ASU 2016-09. During the three months ended March 31, 2020, we recognized a discrete tax benefit of $5.1 million for a return

29

Table of Contents

to provision true-up adjustment. Excluding the impact of these discrete tax benefits, our effective tax rate for the three months ended March 31, 2019 and 2020 was 28.6% and 23.7%, respectively.

​

Results of Operations for the Nine Months Ended March 31, 2019 (YTD Q3 2019) Compared to the Nine Months Ended March 31, 2020 (YTD Q3 2020) (amounts in millions)

​

Net Revenues

​

The table below and the discussion that follows are based upon the way in which we analyze our business. See Note 11 to the condensed consolidated financial statements for additional information about our business segments.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | YTD Q3 | ​ | % of | ​ | YTD Q3 | ​ | % of | ​ |  | ​ | ​ |  |
​ |  | 2019 |  | Net Revenues |  | 2020 |  | Net Revenues |  | $ Change |  | % Change |
Security | ​ | $ | 552.1 |  | 63 | % | $ | 578.5 |  | 65 | % | $ | 26.4 |  | 5 | %
Healthcare | ​ |  | 138.7 |  | 16 | ​ |  | 127.9 |  | 14 | ​ |  | (10.8) |  | (8) | ​
Optoelectronics and Manufacturing | ​ |  | 182.9 |  | 21 | ​ |  | 182.7 |  | 21 | ​ |  | (0.2) |  | — | ​
Total net revenues | ​ | $ | 873.7 |  | 100 | % | $ | 889.1 |  | 100 | % | $ | 15.4 |  | 2 | %

​

Revenues for the Security division during the nine months ended March 31, 2020 increased on a year-over-year basis as a result of increased product revenue from cargo and vehicle inspection systems, explosive detection systems and checkpoint equipment, partially offset by decreases in sales of explosive trace detection products. Service revenue for the Security division was comparable to the prior year period.

​

Revenues for the Healthcare division during the nine months ended March 31, 2020 decreased year-over-year due to lower sales of patient monitoring systems.

​

Revenues for the Optoelectronics and Manufacturing division during the nine months ended March 31, 2020 were consistent with the prior comparable period.

​

Toward the end of the third quarter of fiscal year 2020, revenues in our Security and Optoelectronics and Manufacturing divisions were adversely impacted as a result of the COVID-19 pandemic.

​

​

Gross Profit

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | YTD Q3 | ​ | % of | ​ | YTD Q3 | ​ | % of |
​ |  | 2019 |  | Net Revenues |  | 2020 |  | Net Revenues |
Gross profit | ​ | $ | 317.6 |  | 36.3 | % | $ | 319.1 |  | 35.9 | %

​

Gross profit as a percentage of net revenues during the nine months ended March 31, 2020 decreased on a year-over-year basis as a result of a reduction in gross margin in the Security division, due largely to an unfavorable mix of revenues driven by higher equipment sales growth relative to service revenue growth. Service revenues in the Security division generally carry higher gross margins than equipment sales. The decrease in net revenues from the Healthcare division also adversely impacted the gross margin since sales from our Healthcare division generally have higher gross margins than our other divisions. These impacts on gross margin were partially offset by an increase in the gross margin within the Optoelectronics and Manufacturing division due to a favorable sales mix and operational efficiencies.

​

Operating Expenses

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | YTD Q3 | ​ | % of | ​ | YTD Q3 | ​ | % of | ​ |  | ​ | ​ |  |
​ |  | 2019 |  | Net Revenues |  | 2020 |  | Net Revenues |  | $ Change |  | % Change |
Selling, general and administrative | ​ | $ | 196.1 |  | 22.4 | % | $ | 191.7 |  | 21.6 | % | $ | (4.4) |  | (2.3) | %
Research and development | ​ |  | 40.3 |  | 4.6 | ​ |  | 44.5 |  | 5.0 | ​ |  | 4.2 |  | 10.5 | ​
Impairment, restructuring and other charges (benefit), net | ​ |  | 1.1 |  | 0.1 | ​ |  | 1.5 |  | 0.2 | ​ |  | 0.4 |  | 31.7 | ​
Total operating expenses | ​ | $ | 237.5 |  | 27.1 | % | $ | 237.7 |  | 26.7 | % | $ | 0.2 |  | 0.1 | %

​

30

Table of Contents

Selling, general and administrative. SG&A expense for the nine months ended March 31, 2020 was lower than the prior comparable period due to lower sales commissions and marketing expenses, partially offset by higher employee compensation expense.

​

Research and development. The increase in R&D expense during the nine months ended March 31, 2020 from the same prior-year period reflected increased expenses in our Security division primarily to support new product development.

​

Impairment, restructuring and other charges (benefit). In the first nine months of fiscal year 2020, we incurred impairment, restructuring and other charges, net of $3.3 million related to the exit of a product line in our Healthcare division, $1.6 million of employee termination and facility closure costs and $0.3 million of acquisition costs, which were offset by a net recovery of $3.7 million for certain legal costs through insurance reimbursements. In the first nine months of fiscal 2019, we incurred restructuring and other charges of $3.7 million related to employee termination and business exit costs and $0.3 million in acquisition costs, which were partially offset by a $2.8 million net recovery of certain legal costs as a result of insurance reimbursements.

​

Other Income and Expenses

​

Interest and other expense, net. For the nine months ended March 31, 2020, interest and other expense, net was $14.3 million as compared to $16.5 million in the comparable prior-year period. This decrease was driven primarily by lower average levels of borrowing under our revolving credit facility as well as a lower average interest rates during the nine months ended March 31, 2020 compared to the same period in the prior year. Interest expense in the current-year period included $6.6 million of non-cash interest expense largely related to the Notes (see Note 6 to the condensed consolidated financial statements for further discussion) compared to $5.8 million during the comparable prior-year period.

​

Income taxes. For the nine months ended March 31, 2020, we recognized a provision for income taxes of $5.8 million compared to $15.4 million for the comparable prior-year period. The effective tax rate for the nine months ended March 31, 2019 and 2020 was 24.2% and 8.7%, respectively. During the nine months ended March 31, 2019 and 2020, we recognized discrete tax benefits of $2.6 million and $12.0 million, respectively, primarily for equity-based compensation under ASU 2016-09 in each period and a return to provision true-up adjustment in the third quarter of fiscal year 2020. Excluding the net impact of these discrete tax benefits, our effective tax rate for the nine months ended March 31, 2019 and 2020 was 28.4% and 26.7%, respectively.

​

Liquidity and Capital Resources

​

Our principal sources of liquidity are our cash and cash equivalents, cash generated from operations and our credit facility. Cash and cash equivalents totaled $101.0 million as of March 31, 2020, a increase of $4.7 million, or 4.9%, from $96.3 million as of June 30, 2019. During the nine months ended March 31, 2020, we generated $105.6 million of cash flow from operations. We currently anticipate that our available funds, cash flow from operations and credit facilities will be sufficient to meet our operational cash needs for the next 12 months and the foreseeable future.

​

Our current revolving credit facility allows us to borrow up to $535 million and matures in April 2024. As of March 31, 2020, there was $95.0 million outstanding under the revolving credit facility and $48.1 million outstanding under the letters-of-credit sub-facility.

​

Cash Provided by Operating Activities. Cash flows from operating activities can fluctuate significantly from period to period, as net income, adjusted for non-cash items, and working capital fluctuations impact cash flows. During the nine months ended March 31, 2020, we generated $105.6 million of cash from operations compared to $87.7 million in the same prior-year period. The increase in operating cash flow was driven by higher net income and an improvement in working capital

​

Cash Used in Investing Activities. Net cash used in investing activities was $28.3 million for the nine months ended March 31, 2020 compared to $40.8 million used for the nine months ended March 31, 2019. During the nine months ended March 31, 2020, we used cash of $16.1 million for capital expenditures, $3.5 million primarily for the acquisition of an optoelectronics business and $8.8 million for the acquisition of intangible and other assets. During the nine months ended March 31, 2019, we used cash of $20.9 million for capital expenditures, $17.5 million for the acquisition of an optoelectronics business and $0.8 million for the acquisition of a Security services business.

​

Cash Used in Financing Activities. Net cash used in financing activities was $68.5 million for the nine months ended March 31, 2020 compared to $23.3 million for the nine months ended March 31, 2019. During the nine months ended March 31, 2020, our primary uses in financing were $78.5 million for repurchases of our common stock and tax payments related to net share settlements of equity awards, partially offset by $7.0 million of net borrowings on our revolving credit facility and $8.4 million of proceeds from exercise of stock options and the employee stock purchase plan. During the nine months ended March 31, 2019, our primary uses of financing

31

Table of Contents

were $34.8 million used for share repurchases and taxes paid related to the net share settlement of equity awards , partially offset by $11.0 million borrowed under our revolving credit facility.

​

Borrowings

​

See Note 6 to the condensed consolidated financial statements for a detailed discussion regarding our revolving credit facility and our Notes.

​

Cash Held by Foreign Subsidiaries

​

Our cash and cash equivalents totaled $101.0 million at March 31, 2020. Of this amount, approximately 64% was held by our foreign subsidiaries and subject to repatriation tax considerations. These foreign funds were held primarily by our subsidiaries in Singapore, the United Kingdom, Malaysia, Mexico, Canada and Australia and to a lesser extent in Germany, India, and Albania among other countries. We intend to permanently reinvest certain earnings from foreign operations, and we currently do not anticipate that we will need this cash in foreign countries to fund our U.S. operations. In the event we repatriate cash from certain foreign operations and taxes have not previously been withheld on the related earnings, we would provide for withholding taxes at the time we change our intention with regard to the reinvestment of those earnings.

​

Issuer Purchases of Equity Securities

The following table contains information about the shares of common stock we purchased during the quarter ended March 31, 2020:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Maximum number (or
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | approximate dollar
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | value) of
​ | ​ | ​ | ​ | ​ | ​ | ​ | Total number of | ​ | shares (or
​ | ​ | ​ | ​ | ​ | ​ | ​ | shares (or units) | ​ | units)
​ | ​ | ​ | ​ | ​ | ​ | ​ | purchased as | ​ | that may
​ | ​ | Total number of | ​ | Average price | ​ | part of publicly | ​ | yet be purchased
​ | ​ | shares (or units) | ​ | paid per share (or | ​ | announced plans or | ​ | under the plans or
​ |  | Purchased |  | unit) |  | programs |  | programs (1)
January 1 to January 31, 2020 |  | 28,303 | ​ | $ | 89.71 |  | 28,303 |  | 267,530
February 1 to February 29, 2020 |  | 146,808 | ​ | ​ | 88.27 |  | 146,808 |  | 120,722
March 1 to March 31, 2020 |  | 120,722 | ​ | ​ | 76.90 |  | 120,722 |  | —
​ |  | 295,833 | ​ | ​ | ​ |  | 295,833 | ​ | ​

(1) | In March 2018, the Board of Directors authorized a stock repurchase program of up to 1,000,000 shares which was fully utilized as of March 31, 2020. In April 2020, the Board of Directors authorized a new share repurchase program of up to 1,000,000 shares. Upon repurchase, the shares are restored to the status of authorized but unissued, and we record them as a reduction in the number of shares of common stock issued and outstanding in the consolidated financial statements.

​

Contractual Obligations

​

During the nine months ended March 31, 2020, there were no material changes outside the ordinary course of business in the information regarding specified contractual obligations contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019. See Notes 1, 6 and 9 to the condensed consolidated financial statements for additional information regarding our contractual obligations.

​

Off-Balance Sheet Arrangements

​

As of March 31, 2020, we did not have any significant off-balance sheet arrangements, as defined in Item 303(a)(4) of Regulation S-K.

​

Recent Accounting Pronouncements

​

For information with respect to recent accounting pronouncements and the potential impact of those pronouncements on our condensed consolidated financial statements, see Note 1 to the condensed consolidated financial statements.

​

32

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

​

For a discussion of our exposure to market risk, refer to our market risk disclosures set forth in Part II, Item 7A “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019. There have been no material changes to our exposure to market risk during the nine months ended March 31, 2020 from that described in the Annual Report.

​

ITEM 4. CONTROLS AND PROCEDURES

​

Evaluation of Disclosure Controls and Procedures

​

As of March 31, 2020, the end of the period covered by this report, our management, including our Chief Executive Officer and our Chief Financial Officer, reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act). Based upon management's review and evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the SEC and is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

​

Changes in Internal Control over Financial Reporting

​

There were no changes in our internal control over financial reporting during the third quarter of fiscal 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

Limitations on Effectiveness of Controls and Procedures

​

In designing and evaluating our controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud within the Company have been detected.

​

​

33

Table of Contents

PART II—OTHER INFORMATION

​

ITEM 1. LEGAL PROCEEDINGS

​

The material legal proceedings in which we are involved are discussed in Note 9, “Commitments and Contingencies,” of the Notes to the Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q, and are hereby incorporated by reference.

​

ITEM 1A. RISK FACTORS

​

The discussion of our business, operations, and financial results in this Quarterly Report on Form 10-Q for the period ended March 31, 2020 should be read together with the risk factors contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019, filed with the SEC on August 27, 2019, which describe various risks and uncertainties which could materially affect our business, financial condition and results of operations in the future. Except as set forth below, there have been no material changes to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019. The risks described below and in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and results of operations.

​

The novel coronavirus (COVID-19) outbreak has significantly impacted worldwide economic conditions and could adversely impact our business, financial condition and results of operations.

​

Our operations expose us to risks associated with pandemics, epidemics or other public health emergencies, such as the recent outbreak of COVID-19. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the President of the United States declared the COVID-19 outbreak a national emergency. The outbreak has resulted in governments around the world implementing increasingly stringent measures to help combat the spread of the virus, including quarantines, “shelter in place” and “stay at home” orders, travel restrictions, business curtailments, school closures, and other measures.

​

Many of our products and services are considered to be essential under federal, state and local guidelines. Accordingly, we currently continue to operate across our global footprint; however, given recent government regulations, many of our global facilities are not able to operate at optimal capacity. Notwithstanding our continued operations, COVID-19 has begun to have and may have further negative impacts on our operations, supply chain, transportation networks and customers, which may compress our margins, including as a result of preventative and precautionary measures that we, other businesses and governments are taking. The COVID-19 outbreak is a widespread public health crisis that is adversely affecting the economies and financial markets of many countries which may result in a period of regional, national, and global economic slowdown or regional, national, or global recessions. Any resulting economic downturn or slowdown could curtail or delay spending, adversely affect demand for our products and contribute to volatile supply and demand conditions affecting prices and volumes in the markets for our products, services and raw materials. The progression of this matter could also negatively impact our business or results of operations through the temporary closure of our operating locations or those of our customers or suppliers, disrupting raw materials to our factories and assembly plants, inhibiting the manufacture and assembly of products at our factories and assembly plants, delaying or preventing deliveries to our customers, and interruption of our ability to provide servicing and installations of equipment due to travel restrictions, among others.

​

In addition, the ability of our employees and employees of our suppliers and customers to work may be significantly impacted by individuals contracting or being exposed to COVID-19, or as a result of the control measures noted above, which may significantly hamper our production throughout the supply chain and constrict sales channels. Our customers may be directly impacted by business curtailments or weak market conditions and may not be willing or able to fulfill their contractual obligations or open letters of credit and may seek to modify or terminate their contracts with us. We may also experience delays in obtaining letters of credit or processing letter of credit payments due to the impacts of COVID-19 on foreign issuing and U.S. intermediary banks. In addition, the COVID-19 pandemic may create an increased risk of customer defaults or delays in payments. Our customers may terminate or amend their agreements for the purchase or service of our products due to bankruptcy, lack of liquidity, lack of funding, operational failures, or other reasons.

​

Further, while we currently do not anticipate issues under our credit agreements, events resulting from the effects of the COVID-19 pandemic may negatively impact our ability to comply with our financial covenants in the future, which could lead us to seek an amendment or waivers from our lenders, limit access to or require accelerated repayment of our existing credit facilities, or require us to pursue alternative financing. We have no assurance that any such alternative financing, if required, could be obtained at terms acceptable to us, or at all, including as a result of the effects of COVID-19 on financial markets at such time.

​

34

Table of Contents

The extent to which COVID-19 may adversely impact our business depends on future developments, which are highly uncertain and unpredictable, including new information concerning the severity of the outbreak and the effectiveness of actions globally to contain or mitigate its effects. As we cannot predict the duration or scope of the COVID-19 pandemic, the estimated negative impact to our results of operations, cash flows and financial position cannot be reasonably estimated but might be material and last for an extended period of time.

​

Substantial declines in crude oil prices or extended periods of low crude oil prices may adversely affect our business, financial condition, and results of operations.

​

Some of our international customers have procurement budgets that are strongly correlated with fluctuations in the price of crude oil. Historically, the market for crude oil has been volatile and unpredictable. Crude oil prices are subject to rapid and significant fluctuations in response to global events and relatively minor changes in supply and demand. Recently, as a result of increased supply and decreased demand, crude oil prices have declined sharply. While factors relating the price of crude oil to demand for our products and services are complex, this period of depressed crude oil prices may adversely affect our business, financial condition, and results of operations.

​

If we are unable to continue or fail to perform on our existing agreements to provide security screening solutions to customers after expending substantial resources, such failure could have a material adverse effect on our business, financial condition and results of operations.

​

Certain of our projects require the expenditure of substantial management and financial resources in anticipation of future revenue generation. For example, our contract with the Mexican government to provide a turnkey security screening solution at various sites throughout Mexico required substantial expenditures for capital equipment and infrastructure and is set to expire on May 13, 2020. While we are actively in discussions with the Mexican government for a renewal of the program, we cannot provide any assurance that this program will be continued and, if the program is continued, upon what terms. If the program is discontinued or continued upon modified terms, our results of operations could be materially and adversely affected. We anticipate that future contracts for turnkey security screening solutions in other territories could also require the outlay and management of substantial financial resources for capital equipment and infrastructure.

​

Turnkey screening solutions projects, in contrast to the sale and installation of security inspection equipment, also require that we hire and manage large numbers of local personnel in jurisdictions where we may not have previously operated. They also require that we establish, adhere to, adapt and monitor operating procedures over periods that last much longer than our other projects. If we are unable to efficiently manage the adaptation and growth of our operations relating to these projects, our operations could be materially and adversely affected.

​

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

​

See Issuer Purchases of Equity Securities discussion under Part I, Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations, which is hereby incorporated by reference.

​

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

​

None

​

ITEM 4. MINE SAFETY DISCLOSURES

​

Not applicable

​

ITEM 5. OTHER INFORMATION

​

None

​

35

Table of Contents

ITEM 6. EXHIBITS

​

Exhibit Number |  | Description
31.1 | ​ | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
​ | ​ | ​
31.2 | ​ | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
​ | ​ | ​
32.1 | ​ | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
​ | ​ | ​
32.2 | ​ | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
​ | ​ | ​
101.INS | ​ | XBRL Instance Document
​ | ​ | ​
101.SCH | ​ | Inline XBRL Taxonomy Extension Schema
​ | ​ | ​
101.CAL | ​ | Inline XBRL Taxonomy Extension Calculation Linkbase
​ | ​ | ​
101.DEF | ​ | Inline XBRL Taxonomy Extension Definition Linkbase
​ | ​ | ​
101.LAB | ​ | Inline XBRL Taxonomy Extension Label Linkbase
​ | ​ | ​
101.PRE | ​ | Inline XBRL Taxonomy Extension Presentation Linkbase
​ | ​ | ​
104 | ​ | Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

​

​

36

Table of Contents

Signatures

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, in the City of Hawthorne, State of California on the 1st day of May 2020.

​

​ | ​ | ​
​ | OSI SYSTEMS, INC.
​ | ​ | ​
​ | By: | /s/ Deepak Chopra
​ | ​ | Deepak Chopra
​ | ​ | President and Chief Executive Officer
​ | ​ | (Principal Executive Officer)
​ | ​ | ​
​ | By: | /s/ Alan Edrick
​ | ​ | Alan Edrick
​ | ​ | Executive Vice President and Chief Financial Officer
​ | ​ | (Principal Financial and Accounting Officer)

​

​

37